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Abstract 
Membrane-type 1 matrix metalloproteinase (MT1-MMP) is a multifunctional protease that 
invokes changes extracellularly via cleavages of ECM substrates, and intracellularly through 
induction of cell signalling cascades, both to influence cell behaviour and motility. The 
effects of MT1-MMP activation, MMP catalytic activity, and ERK1/2 signalling were 
examined by chemically or genetically altering each parameter. Regardless of treatment, 
expression of the two gelatinases, MMP-2 and -9, were always altered in an inverse 
relationship. This work proposes a pathway through active MT1-MMP initiation of ERK1/2 
phosphorylation and subsequent targeting the NF-κB transcription factor, to ultimately 
influence MMP-9 expression. Modulation of MT1-MMP activation, activity, or downstream 
signalling, all resulted in decreased invasive potential in MDA-MB-231 breast cancer cells. 
In a chicken embryo tumour model, only untreated MDA-MB-231 cells caused tumour 
vascularization and complete wound closure. Furthermore, these results suggest that cells 
lacking active MT1-MMP, phospho-ERK1/2, or adequate MMP-9, have considerably 
reduced invasive potential. 
 
Keywords 
Extracellular matrix, matrix metalloproteinases, MT1-MMP, MMP-2, MMP-9, phospho-
ERK1/2, cell invasion, 3D cell culture 
 
 
 ii 
 
Acknowledgments 
First and foremost, thank you to my supervisor, Dr. Sashko Damjanovski for accepting me 
into your laboratory as an undergraduate student and further allowing me to grow as a 
graduate student. Thank you for your endless academic feedback, life advice, and support of 
my future endeavors. My experiences over the last three years in your laboratory have 
instilled skills that I will carry with me far outside of my time at Western.  
Thank you to my advisors Dr. Thomas Drysdale and Dr. Alex Timoshenko for their feedback 
and guidance throughout my academic accomplishments over the past two years. 
Additionally, thank you to Dr. Rob Cumming, Dr. Greg Kelly, and Dr. Hon Leong, for their 
generosity in providing the use of equipment and resources essential to the completion of this 
project. To the past and present members of the Dr. Cumming, Dr. Kelly, and Dr. 
Timoshenko labs, thank you for your collegiality, scientific opinions, and willingness to offer 
help when help is needed. It has been a pleasure being in this department with you all. 
I would also like to acknowledge those in the Damjanovski lab, Mario Cepeda, Jessica 
Willson, Jacob Pelling, and Carlie Muir, for making this academically challenging 
experience feel easier through your friendship. Jake, thank you for being my other half, my 
second opinion, my biggest critic, but also my most supportive friend throughout this 
process. To say my time in graduate school without you would have turned out the same is 
impossible.  
Most importantly, Mario Cepeda, thank you for recognizing my potential early on and 
continuing to challenge me to push my limits. Your mentorship and friendship over the past 
two years have been a true testament to my achievements. From your passion for science and 
indispensible work ethic, I have no doubt that you will go on to continue to exceed 
expectations and achieve great success in both your academic endeavors and personal life 
goals. I wish you nothing but the best.  
 iii 
 
Table of Contents 
Abstract ................................................................................................................................ i 
Acknowledgments............................................................................................................... ii 
Table of Contents ............................................................................................................... iii 
List of Tables .................................................................................................................... vii 
List of Figures .................................................................................................................. viii 
List of Abbreviations .......................................................................................................... x 
Chapter 1 ............................................................................................................................. 1 
1 Introduction .................................................................................................................... 1 
1.1 The Extracellular Matrix ......................................................................................... 1 
1.2 Key ECM Remodelers and Inhibitors: Matrix Metalloproteinases and Tissue 
Inhibitor of Metalloproteinases ............................................................................... 2 
1.3 MT1-MMP Structure, Activation, and Function in Development and Disease ..... 4 
1.4 Ras-Raf-MEK-ERK Mitogen-Activated Protein Kinase Cascade ......................... 7 
1.5 The Gelatinases: MMP-2 and MMP-9 .................................................................... 8 
1.6 Proteolytic and Non-Proteolytic Functions of MT1-MMP in Promoting Cell 
Motility ................................................................................................................. 12 
1.7 Development of Synthetic MMP Inhibitors as Cancer Therapeutics ................... 13 
1.8 Hypothesis and Objectives .................................................................................... 14 
Chapter 2 ........................................................................................................................... 18 
2 Material and Methods .................................................................................................. 18 
2.1 Cell Culture Conditions ........................................................................................ 18 
 Generation of 231-PDX Stable Cell Line ................................................................ 19 
2.2 19 
2.3 Generation of MDA-MB-231 and 231-PDX ZsGreen Stable Cell Lines ............. 19 
tumour assay. ............................................................................................................... 22 
 iv 
 
2.4 Chemical Inhibitors ............................................................................................... 22 
2.5 RNA Extraction and Quantitative real-time PCR ................................................. 22 
2.6 Antibodies ............................................................................................................. 22 
2.7 Protein Collection and Immunoblotting................................................................ 22 
2.8 Generation of MMP-2 Conditioned Medium for Cell Culture Treatment ............ 23 
2.9 Gelatin Zymography and Reverse Gelatin Zymography ...................................... 24 
2.10 Firefly Luciferase Transcriptional Activity Assay ............................................... 24 
2.11 Scratch Wound Closure Migration Assay ............................................................. 25 
2.12 Transwell Cell Motility Assays ............................................................................ 25 
2.13 Three Dimensional (3D) Cell Culture................................................................... 26 
2.14 Avian Embryo Tumour Vascularization Assay .................................................... 27 
2.15 Densitometry Analysis .......................................................................................... 28 
2.16 Statistical Analysis ................................................................................................ 28 
Chapter 3 ........................................................................................................................... 30 
3 Results .......................................................................................................................... 30 
3.1 MEK1/2 inhibitor altered MMP-2 and MMP-9 mRNA levels in MCF-7 MT1-
MMP C2 and MDA-MB-231 cells ....................................................................... 30 
3.2 Inhibition of MT1-MMP catalytic site increased total MT1-MMP protein levels 
and altered subsequent MMP-2 and MMP-9 mRNA levels in MCF-7 and MDA-
MB-231 breast cancer cells ................................................................................... 35 
3.3 Inhibiting pro-MT1-MMP activation changed MMP-2 and MMP-9 mRNA levels 
and resulted in altered migratory and invasive potential in MCF-7 and MDA-MB-
231 breast cancer cells .......................................................................................... 38 
3.4 Low levels of pro-MT1-MMP and high levels of active MT1-MMP in stable 
MT1-MMP overexpression MDA-MB-231 cell lines resulted in increased MMP-9 
mRNA levels ......................................................................................................... 49 
3.5 MEK1/2 inhibitor decreased NF-κB transcription while AP-1 transcription was 
unaffected in MCF-7 MT1-MMP and MDA-MB-231 breast cancer cells ........... 52 
3.6 Only MDA-MB-231 cells treated with MERK1/2 inhibitor exhibited both reduced 
migratory and invasive potential ........................................................................... 52 
 v 
 
3.7 MDA-MB-231 cells with decreased ERK1/2 phosphorylation, inhibited MMP 
catalytic activity, or altered MT1-MMP activation all exhibited morphological 
changes in 3D cell culture ..................................................................................... 58 
3.8 Changes in MT1-MMP activation, ERK1/2 phosphorylation, and MMP-2 and 
MMP-9 mRNA levels in vitro contributed to in vivo tumour growth ................... 61 
Chapter 4 ........................................................................................................................... 65 
4 Discussion .................................................................................................................... 65 
4.1 Inhibiting ERK1/2 phosphorylation inversely effects gelatinase expression, 
reduces total MT1-MMP active protein levels, and decreases migratory and 
invasive potential of breast cancer cells................................................................ 65 
4.1.1 Decreasing ERK1/2 phosphorylation increased MMP-2 mRNA levels, but 
decreased MMP-9 mRNA levels in MCF-7 MT1-MMP C2 and MDA-MB-231 breast 
cancer cells ................................................................................................................... 66 
4.1.2 Decreased migratory and invasive potential is observed with decreased phospho-
ERK1/2 in vitro, ex vivo, and in vivo in MDA-MB-231 breast cancer cells................ 68 
4.2 Inhibiting MMP catalytic activity increases total MT1-MMP active protein levels, 
inversely effects gelatinase expression, and decreases invasive potential of breast 
cancer cells ............................................................................................................ 72 
4.2.1 Inhibition of MMP activity by BB-94 addition decreased MMP-2 mRNA levels, but 
increased MMP-9 mRNA levels in MCF-7 MT1-MMP C2 and MDA-MB-231 breast 
cancer cells ................................................................................................................... 72 
4.2.2 Inhibition of MMP cleavage activity does not affect migration, but does decrease 
invasive potential of MDA-MB-231 breast cancer cells.............................................. 74 
4.3 MT1-MMP overexpression in MDA-MB-231 breast cancer cells altered pro- and 
active forms of MT1-MMP and inversely affects gelatinase expression ............. 76 
4.4 Inhibiting furin convertase activity alters MT1-MMP activation, inversely effects 
gelatinase expression, and alters cell migratory and invasive potential ............... 77 
4.4.1 Chemical inhibition of furin decreased levels of active MT1-MMP, phospho-
ERK1/2, and MMP-9 mRNA, but increased MMP-2 mRNA, and did not change cell 
migratory ability ........................................................................................................... 78 
4.4.2 Overexpression of α1-PDX increased active MT1-MMP, phospho-ERK1/2, MMP-9 
mRNA levels, but decreased MMP-2 mRNA in MDA-MB-231 cells ........................ 79 
4.4.3 Overexpression of α1-PDX in MDA-MB-231 cells exhibit decreased migration and 
invasive potential ......................................................................................................... 80 
Chapter 5 ........................................................................................................................... 82 
 vi 
 
5 Conclusion ................................................................................................................... 82 
References .................................................................................................................... 87 
Curriculum Vitae .............................................................................................................. 96 
 vii 
 
List of Tables  
Table 1. A comparison of the relative levels of MT1-MMP and phospho-ERK1/2 protein, 
gelatinase expression, and invasive potential of MCF-7, MCF-7 MT1-MMP C2, MDA-MB-
231, and 231-PDX breast cancer cells. ................................................................................... 16 
Table 2. Origin, classification, and key characteristics of MCF-7 and MDA-MB-231 breast 
cancer cell lines. ...................................................................................................................... 17 
Table 3. Select chemical inhibitors used to treat MCF-7 and MDA-MB-231 cells, targeting 
ERK1/2 phosphorylation, MMP catalytic activity and MT1-MMP activation. ..................... 20 
Table 4. Primer sequences used for qPCR. ............................................................................. 21 
 
 viii 
 
List of Figures  
Figure 1. Only MMP-9 contains binding sites for transcription factors AP-1 and NF-κB 
within its promoter region. ...................................................................................................... 11 
Figure 2. Phosphorylated ERK1/2 mediates an inverse relationship between MMP-2 and 
MMP-9 gene expression in MCF-7 breast cancer cells. ......................................................... 32 
Figure 3. Phosphorylated ERK1/2 mediates an inverse relationship between MMP-2 and 
MMP-9 gene expression in MDA-MB-231 breast cancer cells. ............................................. 34 
Figure 4. Inhibition of ERK1/2 phosphorylation and MT1-MMP catalytic site changes MT1-
MMP pro- and active protein forms and associated MMP-2 and MMP-9 mRNA levels in 
MCF-7 MT1-MMP C2 cells. .................................................................................................. 37 
Figure 5. Inhibition of the MT1-MMP catalytic site does not changes MT1-MMP pro- and 
active protein forms, but does change MT1-MMP, MMP-2, and MMP-9 mRNA levels in 
MDA-MB-231 breast cancer cells. ......................................................................................... 40 
Figure 6. Inhibition of MT1-MMP activation reduces active MT1-MMP levels and ERK1/2 
phosphorylation with subsequent changes MMP-2 and MMP-9 mRNA levels in MCF-7 
MT1-MMP C2 cells. ............................................................................................................... 42 
Figure 7. Chemical inhibition of MT1-MMP activation does not change active MT1-MMP 
levels, but does change MT1-MMP, MMP-2 and MMP-9 mRNA levels in MDA-MB-231 
breast cancer cells. .................................................................................................................. 46 
Figure 8. Overexpression of α1-PDX in MDA-MB-231 breast cancer cells alters MT1-MMP 
activation causing changes in MT1-MMP protein forms, ERK1/2 phosphorylation, and MMP 
expression. .............................................................................................................................. 48 
Figure 9. MT1-MMP over-expression in MDA-MB-231 breast cancer cells alters pro- and 
active MT1-MMP protein forms and subsequently results in distinct inverse relationships 
between MMP-2 and MMP-9 gene expression. ...................................................................... 51 
 ix 
 
Figure 10. Inhibition of ERK1/2 phosphorylation affects transcription of NF-κB more 
strongly than inhibition of MT1-MMP catalytic site activity in breast cancer cells. ............. 54 
Figure 11. Inhibition of ERK1/2 phosphorylation is more influential on cell migration and 
invasion than inhibition of MMP enzymatic activity or MT1-MMP activation. .................... 57 
Figure 12. Interfering with MT1-MMP activation, MT1-MMP catalytic activity, and MAPK 
signalling affects 3D morphology of MDA-MB-231 breast cancer cells. .............................. 60 
Figure 13. MDA-MB-231 breast cancer cells treated with U0126 showed fewer incidences of 
vascularization and wound closure within avian CAM. ......................................................... 63 
Figure 14. Proposed cell models individually outlining cellular outcomes of inhibiting 
ERK1/2 phosphorylation, MMP catalytic activity, or altering of MT1-MMP activation via 
changes in MMP transcription and protein levels, ERK1/2 phosphorylation, and cell motility.
................................................................................................................................................. 85 
 
 
 
 
 
 
 
 
 
 
 x 
 
List of Abbreviations 
2D   Two-dimensional 
3D   Three-dimensional 
α1-PDX  Alpha1-antitrypsin Portland 
ANOVA  Analysis of variance 
AP-1   Activator protein 1 
ARP2/3  Actin related proteins 2 and 3 
BCA   Bicinchoninic acid  
BM   Basement membrane 
BSA   Bovine serum albumin 
CAM   chorioallantoic membrane 
CBD   Collagen binding domain 
cDNA   Complimentary deoxyribonucleic acid 
CD44   Cluster designation 44 
CHO   Chinese hamster ovary 
CM   Conditioned media 
DAPI   4',6-diamidino-2-phenylindole 
DMEM  Dulbecco's Modified Eagle Medium 
DMSO   Dimethyl sulfoxide 
ECM   Extracellular matrix 
EDTA   Ethylenediaminetetraacetic acid 
EGF   Epidermal growth factor 
ER   Estrogen receptor 
ERK   Extracellular regulated kinase 
FBS   Fetal bovine serum 
 xi 
 
FGF   Fibroblast growth factor 
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase 
HER2   Human epidermal growth factor receptor 2 
IF-1β   Interleukin 1 beta 
JNK   c-Jun N-terminal kinase 
KRE   Keratinocyte differentiation-factor responsive element 
MAPK   Mitogen-activated protein kinase 
MAPKK  Mitogen-activated protein kinase kinase 
MAPKKK  Mitogen-activated protein kinase kinase kinase 
MCF-7  Michigan Cancer Foundation -7 
MDA-MB-231 MD Anderson Metastatic Breast 231 
MEK   MAPK/ERK kinase 
MLC   Myosin light chain 
MLCK   Myosin light chain kinase 
MMP   Matrix metalloproteinase 
MMPI   Matrix metalloproteinase inhibitor 
mRNA   Messenger ribonucleic acid 
MT-MMP  Membrane-type matrix metalloproteinase 
NF-κB   Nuclear factor κB  
PBS   Phosphate-buffered saline 
Phospho-ERK1/2 Phosphorylated extracellular regulated kinase 1 and 2 
PR   Progesterone receptor 
qPCR   Quantitative (real-time) polymerase chain reaction 
Raf   Rapidly accelerated fibrosarcoma 
RCE   Retinoblastoma control element  
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
 xii 
 
SEM   Standard error of the mean 
TBST   Tris buffered saline with Tween 
TGF-β   Transforming growth factor beta 
TIE   TGF-β inhibitory element 
TIMP   Tissue inhibitor of metalloproteinases 
TNF-α   Tumour necrosis factor alpha 
VEGF   Vascular endothelial growth factor 
WASP   Wiskott-Aldrich syndrome protein 
WNT   Wingless-related integration site 
ZsGreen  Zoanthus species green 
 
1 
 
Chapter 1  
1 Introduction 
1.1 The Extracellular Matrix  
The Extracellular Matrix (ECM) is a three-dimensional, cross-linked structure of secreted 
macromolecules present within all tissues and is essential for life as it regulates 
eukaryotic cell development, function, and homeostasis (Lu et al.,2011; Rozario and 
DeSimone, 2010). The ECM aids in the support, repair, and regeneration of differentiated 
tissues and organs, whereby integrity is maintained through regulation of structural 
proteins, embedded cytokines, growth factors, growth factor receptors, as well as 
maintenance of hydration and pH of the all-encompassing cell-surrounding environment 
(Naba et al., 2012; Sanes, 2003; Torricelli et al., 2013). The functional importance of the 
ECM is illustrated by the wide range of tissue defects or, in severe cases, embryonic 
lethality caused by mutations in genes that encode essential ECM components (Bateman 
et al., 2009; Järveläinen, 2009).  
In mammals, the ECM is composed of approximately 300 different protein types, known 
as the core matrisome, including proteins such as collagen, proteoglycans, and 
glycoproteins (Järveläinen, 2009; Schaefer and Schaefer, 2010). There are two main 
types of ECM that are distinct due their location and composition within tissues: the 
interstitial connective tissue matrix, which surrounds cells and provides structural 
scaffolding for tissues; and the basement membrane, which is a specialized form of ECM 
that separates the epithelium from the underlying stroma. More specifically, the basement 
membrane is comprised predominately of type IV collagen (Martin and Timpl, 1987) and 
functions to provide support for epithelial, endothelial, muscle and fat cells (Paulsson, 
1992; Kalluri, 2003), acts as a mechanical barrier to cells and other macromolecules, and 
serves as sites for cell-ECM adhesions and interactions (Mouw et al., 2014). 
ECM proteins can also function as ligands for various cell surface receptors present on 
the embedded cells, stimulating diverse cell-signalling pathways, which regulate cell 
adhesion, migration, proliferation, apoptosis, survival, or differentiation (Egeblad and 
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Werb, 2002). Furthermore, the ECM sequesters and locally releases growth factors, such 
as epidermal growth factor (EGF), fibroblast growth factor (FGF) and other signalling 
molecules, such as WNTs and transforming growth factor-β (TGF-β), which additively 
influence cell behaviour (Lu et al., 2011). Cells are capable of rebuilding and remodeling 
the ECM through synthesis, degradation, reassembly, and chemical modification of ECM 
components. The principle molecules responsible for degrading and remodeling the ECM 
are Matrix Metalloproteinases (MMPs) and their endogenous inhibitors, Tissue Inhibitors 
of Metalloproteinases (TIMPs) (Lambert et al., 2004). The actions of MMPs and TIMPs 
within the ECM are complex and need to be tightly regulated to maintain tissue 
homeostasis and to respond to developmental cues, as well as physiological stresses, such 
as injury, wound repair, and disease (Järveläinen, 2009; Hynes, and Naba, 2012; Frantz et 
al., 2010). Collectively, the composition and status of the ECM surrounding, supporting, 
and interacting with cells within a given tissue can vary tremendously, whether it is from 
one tissue to another (muscle versus skin versus bone), within a given tissue (atria versus 
ventricle), or from one physiological state to another (embryonic development versus 
adult maintenance versus cancer metastasis) (Zhen and Cao, 2014).  
1.2 Key ECM Remodelers and Inhibitors: Matrix 
Metalloproteinases and Tissue Inhibitor of 
Metalloproteinases 
MMPs comprise a family of zinc-dependent endopeptidases, which function to 
selectively cleave all components of the ECM, resulting in substrate degradation and 
subsequent remodeling. To date, 24 MMPs have been identified in vertebrates and are 
classified into one of five groups based on their structure and ECM substrate specificity: 
collagenases (e.g. MMP-1, -8, -13), gelatinases (MMP-2 and MMP-9), membrane-type 
(MT1-MMP – MT6-MMP), stromelysins (e.g. MMP-3, -10, -11) and matrilysins (e.g. 
MMP-7 and MMP-26) (Bourboulia, and Stetler-Stevenson, 2010). As the list of known 
MMP substrates increases in number and complexity, a more simplistic categorization of 
MMPs has formed, which describes their structure and cellular localization: Membrane-
Type MMPs (MT-MMPs), which are anchored at the cell surface, and secreted MMPs, 
which are soluble in the ECM (Egeblad and Werb, 2002)  
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Most MMPs share a common domain structure, consisting of an N-terminal pro-peptide 
domain, the catalytic domain, and the hemopexin-like domain. Synthesized as inactive 
zymogens, the MMP pro-peptide domain contains a conserved cysteine residue that 
interacts with the catalytic domain to prevent substrate binding. Activation of MMPs 
occurs upon removal of the pro-domain. Membrane-Type MMPs are activated 
intracellularly in the trans-Golgi by a protein-convertase-dependent mechanism, 
principally by furin, and are anchored at the cell membrane in an active form (Sternlicht 
and Werb, 2001). Secreted MMPs are secreted as pro-enzymes and are activated 
extracellullarly by other, already active, proteinases. After activation, within the catalytic 
domain of MMP’s lies the active site, a conserved histidine motif (HEXXHXXGXXH) in 
which the three histidine residues are essential for zinc chelation and subsequent catalytic 
activity (Stöcker and Bode, 1995). The hemopexin-like domain (located at the C-terminal 
end of secreted MMPs) is comprised of a four bladed β-propeller structure, which dictates 
substrate specificity and mediates protein-protein interactions (Visse and Nagase, 2003). 
Moreover, Membrane-Type MMPs contain an N-terminal pro-domain, catalytic domain, 
and a hemopexin-like domain, but with the addition of a transmembrane domain for 
anchorage into the cell membrane and the C-terminal cytoplasmic tail essential for 
localization and recycling to the membrane surface. Collectively, the catalytic domain 
and hemopexin-like domain in all MMP family members, allow these proteins to function 
proteolytically, to achieve ECM degradation and remodeling, and non- proteolytically, by 
binding of extracellular or cell surface proteins to initiate down stream signalling 
pathways (Strongin, 2010). 
MMPs were initially discovered in tadpole metamorphosis during tail resorption, where 
collagen triple helix degradation was detected, marking the earliest observation of MMP 
mediated ECM remodeling (Gross and Lapiere, 1962). Since this discovery, MMPs have 
been documented to degrade all constituents of the ECM, promoting both cell migration 
and influencing cell behaviour through growth factor availability. Additionally, more 
recent evidence has demonstrated that MMPs are also capable of cleaving chemokines, 
growth factor receptors, and cell adhesion molecules (Egeblad and Werb, 2002). 
Therefore, not only can MMPs influence cell behavior by regulating the integrity and 
composition of the ECM with which a cell interacts, but also by regulating the levels of 
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available growth factors and their receptors through cleavage of ECM and non-ECM 
proteins.  
In order to maintain tissue integrity, the correct MMPs must be present at the correct 
time, in the correct location, and in the appropriate form (inhibited or active). Control of 
MMP-dependent cleavages of the ECM is critical in order to maintain proper organismal 
development and maintenance of normal adult tissues. Retaining proper MMP activity in 
tissues is achieved through regulation of MMP gene expression, pro-enzyme activation, 
and the level of their enzymatic activity through catalytic inhibition by their endogenous 
inhibitors, Tissue Inhibitors of Metalloproteinases (TIMPs) (Visse and Nagase, 2003). 
Currently, there are 4 defined mammalian TIMPs (TIMP 1-4), all of which are small-
secreted proteins consisting of structurally and functionally distinct N- and C-terminal 
domains. TIMP N-terminal domains are responsible for direct inhibition of MMP activity 
by binding, and therefore blocking, the MMP catalytic site (Nagase et al., 2006). TIMP 
C-terminal domains interact with the hemopexin domains of select MMPs to aid in MMP 
activation (Stetler-Stevenson, 2008), as well as carry out various MMP-independent 
functions, such as binding to a variety cell surface receptors to induce downstream 
signalling cascades (Stetler-Stevenson and Seo, 2005). 
1.3 MT1-MMP Structure, Activation, and Function in 
Development and Disease 
Unlike secreted MMPs, which are activated extracellullarly and may diffuse freely 
throughout the ECM, Membrane-Type MMPs (MT-MMPs) are activated intracellularly 
and embedded in the plasma membrane; thus, the activities of MT-MMPs are limited to 
the surface of the cells that produced them (Seiki, 2003). Of the six MT-MMPs, MT1-
MMP (also known as MMP-14) was the first identified and most well characterized. 
MT1-MMP plays an integral role in ECM remodeling, as it possesses both proteolytic 
and non-proteolytic functions. Proteolytically, MT1-MMP is directly involved in 
pericellular cleavage of collagen types I, II, and III, laminins-1 and -5, fibronectin, 
vitronectin, fibrin and aggrecan. Additionally, MT1-MMP is responsible for cleavage of 
other cell surface proteins (CD44, cadherins, or integrins), and activation of other 
secreted pro-MMPs most notably pro-MMP-2 and pro-MMP-9 (Toth et al., 2003). Non-
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proteolytically, MT1-MMP interacts with other ECM molecules to stimulate intracellular 
signalling cascades, such as the Mitogen-Activated Protein Kinase (MAPK) pathway, 
resulting in changes in cell behaviour and function (Pahwa et al., 2014). Collectively, 
MT1-MMP is a key regulator of cellular invasion in development and disease.  
MT1-MMP is classified as a type I transmembrane protein, and is synthesized as an 
inactive zymogen, containing a single transmembrane domain important for membrane 
integration and a short cytosolic C-terminal domain essential for regulating cellular 
localization and turnover (Strongin, 2010). The pro-domain of MT1-MMP contains a 
furin cleavage motif; therefore furin is a crucial component in the activation pathway that 
results in active MT1-MMP present on the cell surface. Furin is a specialized serine 
endoproteinase belonging to the protein convertase family. Furin cleaves the multibasic 
motifs R-X-R/K/X-R to transform many pro-proteins into biologically active proteins and 
peptides (Seidah et al., 2008). In humans, furin is ubiquitously expressed, where it is 
primarily localized in the trans-Golgi network and secondarily found in vesicles cycling 
to the cell surface. The importance of furin in proper cell function is illustrated by its 
developmental lethality in furin knockout mice (Scamuffa et al., 2006). Furin and other 
protein convertases are self-activated and, as a result, they initiate proteolytic cascades 
through their wide variety of targets including, MT1-MMP, TGF-β, stromolysin-3 
(MMP-11), growth factors, and adhesion molecules, all of which are essential in the 
processes of cellular transformation, acquisition of the tumourogenic phenotype, and 
metastases formation (Strongin, 2010). The cytosolic C-terminal tail of MT1-MMP is 
important in regulation of cell migration and invasion as the tail of MT1-MMP facilitates 
MT1-MMP localization to invadapodia— cell membrane protrusions that serve as focal 
sites of ECM degradation (Poincloux et al., 2009). Additionally, the tail of MT1-MMP 
has been linked to internalization and turnover of the enzyme with respect to its presence 
on the membrane surface, highlighting the importance of this domain in regulating MT1-
MMP function (Uekita et al., 2001).  
As well as cleaving known ECM substrates, MT1-MMP is involved in the activation of 
pro-MMP-2, which further potentiates the migratory and invasive potential of MT1-
MMP expressing cells through amplified ECM degradation (Itoh et al., 2001). In brief, 
6 
 
during the activation of pro-MMP-2, one MT1-MMP protein acts as a cell surface 
receptor for a TIMP-2, as the inhibitory N-terminus of TIMP-2 binds MT1-MMP at its 
active site. The C-terminal domain of the same TIMP-2 molecule then binds the 
hemopexin-like domain of pro-MMP-2, which can orient the latter into close proximity to 
the active site of a second, adjacent active MT1-MMP. After formation of the MT1-
MMP/TIMP-2/pro-MMP-2 complex, MT1-MMP is in the correct orientation to cleave 
the pro-peptide domain of pro-MMP-2 and release the activated MMP-2 into the ECM 
(Itoh et al., 2001; Lehti et al., 2000). Additionally, the MT1-MMP/TIMP-2/MMP-2 
complex has been shown to activate secreted pro-MMP-9, demonstrating the dependence 
of proper protein associations for subsequent MMP activation events (Toth et al., 2003). 
In conjunction with the activation of pro-MMP-2 and pro-MMP-9, MT1-MMP and 
TIMP-2 can also form an additional complex via the hemopexin domain of MT1-MMP to 
initiate the intracellular cascade of the MAPK pathway leading to the downstream 
phosphorylation of Extracellular Signal-Regulated Kinase (ERK1/2) (Sounni et al., 
2010). Among the cell signalling pathways involved in cancer, the MAPK pathway is one 
of the most prominent, as it regulates diverse cellular functions including cell 
proliferation, survival, angiogenesis, and migration (Fujioka et al., 2006).    
All of the activities MT1-MMP elicits and initiates in the extracellular matrix have 
functions during, and thus impact, development and disease. MT1-MMP is essential for 
proper organismal cellular function during embryogenesis, as knockout of MT1-MMP is 
developmentally lethal in mice. MT1-MMP deficient mice die shortly after birth 
exhibiting craniofacial dysmorphism, arthritis, osteopenia, dwarfism, and fibrosis of soft 
tissues. Of all the 24 known MMP family members, MT1-MMP knockout is the only 
phenotype that is developmentally lethal (Holmbeck et al., 1999), demonstrating the 
importance of proper
 
MT1-MMP function during embryogenesis. Its importance in 
disease is exemplified in pathological conditions, such as cancer, as MT1-MMP promotes 
cell migration and invasion as well as potentiation of ECM remodeling through activation 
of other pro-MMPs. MT1-MMP exhibits increased expression in a wide variety of cancer 
types, classifying MT1-MMP as a pro-invasive and pro-tumourogenic protein. The 
causes of increased MT1-MMP expression in cancer cell types is attributed to 
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transcriptional changes during tumour formation, as there have been no documented 
mutations in the MT1-MMP gene in cancerous cells (Pahwa et al., 2014). 
1.4 Ras-Raf-MEK-ERK Mitogen-Activated Protein Kinase 
Cascade 
Mammalian cells possess four well-characterized MAPKs. The cascades resulting in the 
activation of these MAPK’s are comprised of three protein kinases that act as a signalling 
relay: a MAPK kinase kinase (MAPKKK), which activates a MAPK kinase (MAPKK), 
resulting in the final activation of a MAPK (e.g. ERK1/2, JNK, p38, or ERK5) that 
generally impacts transcription (Roberts, and Der, 2007).  In general, the ERK1/2 
pathway is activated by growth factor-stimulated cell surface receptors, whereas the JNK, 
p38, and ERK5 pathways are activated by stress and growth factors (Mebratu and 
Tesfaigzi, 2009) 
The MAPK pathway of Ras-Raf-MEK1/2-ERK1/2 is of particular interest as ERK1/2 
signalling promotes cell proliferation, cell survival, and cell motility. In this pathway Raf 
is the MAPKKK, MEK1/2 the MAPKK and ERK1/2 the MAPK. Unsurprisingly, this 
pathway is abnormally activated in many cancer types, highlighting the important role of 
ERK1/2 signalling in regulation of proper cell function. During development, ERK1 (44 
kDA) and ERK2 (42 kDa) knockout studies have revealed non-compensatory roles 
between these two proteins, as absence of one is not replaced by the action of the other. 
ERK2 is essential for development as ERK2 knockout mice showed defects in placental 
development resulting in embryonic death, while ERK1 knockout mice were viable, 
fertile, and normal in size (Mebratu and Tesfaigzi, 2009). 
In brief, the Ras-Raf-MEK1/2-ERK1/2 pathway is tightly controlled by a series of 
protein phosphorylation events. Ras directly interacts with Raf, whereby activation of 
MEK1/2 by Raf protein family members leads to the phosphorylation of threonine and 
tyrosine residues within TEY (Thr-Glu-Tyr) recognition sites of ERK1 and ERK2. 
Phosphorylated ERK1/2 can then either be retained within the cytosol or translocated to 
the nucleus, where phospho-ERK1/2 influences gene expression through phosphorylation 
of serine, threonine, or proline residues of downstream transcription factors (Roberts and 
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Der, 2007). Collectively, active phosphorylated ERK1/2 regulates the expression of over 
160 proteins including growth factors, cytokines, cell surface receptors, and MMPs, 
which in turn influence the composition and conditions of the ECM (Meloche and 
Pouysségur, 2007). 
1.5 The Gelatinases: MMP-2 and MMP-9  
The gelatinases, MMP-2 (gelatinase A) and MMP-9 (gelatinase B), differ from other 
MMP family members as they have a collagen-binding domain (CBD) embedded within 
their catalytic domain. The CBD is composed of fibronectin type II repeats and is 
involved in the binding of collagenous substrates, elastin, and fatty acids (Klein, and 
Bischoff, 2011). MMP-2 and MMP-9 are considered potent ECM remodelers as they 
both share the target substrate collagen IV, an abundant component of physiologically 
important basement membranes.  
MMP-2 is synthesized in a 72 kDa pro- form and upon removal of the pro-domain by 
active MT1-MMP, the 63 kDa active form of MMP-2 cleaves a wide variety of substrates 
found within the extracellular milieu (Khasigov et al., 2003). MMP-2 has substrate 
specificity for ECM and non-ECM components such as collagens (I, IV, V, VII, and X), 
gelatin, elastin, fibronectin, laminins, galectin-3, aggrecan, as well as various cell surface 
receptors, growth factors, and chemokines (Järveläinen, 2009). Moreover, active MMP-2 
has the ability to activate pro-MMP-9 to further increase ECM degradation. As a potent 
ECM remodeler with large substrate specificity, altered expression and activity of MMP-
2 has been linked with poor prognosis in multiple cancer types including colorectal, 
melanoma, breast, lung, and prostate. For example, in colorectal cancer many metastatic 
cases involving increased MMP-2 activity have been correlated with increased expression 
in surrounding healthy tissues, in addition to metastatic lesions (Mook et al., 2004).  
MMP-9 is produced as an inactive 92 kDa pro-MMP-9 and degrades both ECM and non-
ECM substrates in an 82 kDa active form (Khasigov et al., 2003). MMP-9 possess 
substrate specificity for collagens III, IV and V, gelatin, elastin, vitronectin, and entactin, 
as well as TNF-α and IL-1β (Järveläinen, 2009). In cancer, MMP-9 contributes to 
angiogenesis of the pre-existing metastatic niche by recruiting macrophages and 
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hematopoietic stem cells (Kaplan et al., 2005; Hiratsuka et al., 2006). In some cases 
metastatic potential of tumors is associated with increased MMP-9 protein levels, and 
down-regulation of MMP-9 depresses metastasis (Björklund and Koivunen, 2005). 
MMP-9 expression is increased through the oncogenic properties of the Ras/Raf pathway 
to activate MEK1/2 and phospho-ERK1/2 (Gum et al., 1997). Phosphorylation of 
ERK1/2 leads to upregulation of MMP-9 transcription factors AP-1 and NF-κB (Fig. 1), 
which can increase transcription of pro-MMP-9 (Lee et al., 2013), ultimately resulting in 
further degradation of the ECM.  
Until recently, the data obtained from most studies suggested that gelatinases played a 
dominant role in basement membrane invasive events because of their ability to degrade 
collagen IV. However, recent studies in cancer cells engineered to express active MMP-2 
and MMP-9 (Hotary et al., 2006) and fibroblasts isolated from MMP- 2−/− and MMP-
9−/− mice (Sabeh et al., 2009) strongly suggest that gelatinases do more than promote 
basement membrane invasion. Recent evidence shows that gelatinases play major, but 
indirect roles in cell signalling by controlling the bioavailability and bioactivity of 
molecules that target specific receptors regulating cell growth, migration, inflammation, 
and angiogenesis. For example, cleavage of laminin-5 by MMP-2 results in the exposure 
of an epitope that enhances endothelial cell migration (Giannelli et al., 2016), while 
MMP-9 can release ECM-sequestered factors VEGF, TGF-β and FGF-2, which stimulate 
proliferation and migration of endothelial cells (Bergers et al., 2000; Yu and 
Stamenkovic, 2000).  
In cancer, there is a loss of tissue organization resulting from aberrant behaviour of ECM 
remodeling proteins. Tumours are characteristically stiffer than the surrounding normal 
tissue resulting from increased ECM deposition and remodeling by MMPs (Butcher et al., 
2009) , which in turn release more chemokines and growth factors embedded within the 
ECM (De Wever et al., 2008). The release of growth factors, such as VEGF by MMP-9, 
enhances vascular permeability and promotes new vessel growth to potentiate tumour 
growth and survival via angiogenesis and cell invasion to ultimately support
10 
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Figure 1. Only MMP-9 contains binding sites for transcription factors AP-1 and NF-
κB within its promoter region.  
Shown are the known cis up-stream regulatory elements in the promoter regions of three 
human MMP genes: MMP-2, MMP-9, and MT1-MMP (MMP-14). The promoters are 
shown in the 5’-3’ direction, with the transcriptional start site indicated by a bent arrow. 
Transcription-factor-binding sites include: the activator proteins (AP)-1 (purple arrows) 
and -2 site, the CCAAT/enhancer-binding protein (C/EBP) site, the cyclic AMP 
response-element binding protein (CREB) site, the early growth response-1 (EGR1) site, 
the keratinocyte differentiation-factor responsive element (KRE), the nuclear factor of κB 
(NF-κB) site (pink arrows), the polyomavirus enhancer-A binding-protein-3 (PEA3) site, 
retinoblastoma control element (RCE), TGF-β inhibitory element (TIE), and the TATA-
box (TATA). The functional activity of the indicated binding sites has been verified by 
either using cell-transfection studies with MMP promoter constructs or functional 
analysis in transgenic mice models. Only the promoter region for MMP-9 contains both 
an AP-1 and NF-κB binding site, while the promoter region for MT1-MMP contains NF-
κB, and the promoter region for MMP-2 contains neither. Adapted from Christopher 
Mark Overall and Carlos López-Otín (2002).  
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metastasis (Butcher et al., 2009; Erler and Weaver, 2009; Paszek et al., 2005). 
1.6 Proteolytic and Non-Proteolytic Functions of MT1-MMP 
in Promoting Cell Motility 
Cell migration and invasion extensively contribute to the development and metastasis of 
cancers. The process of cell migration has been well characterized, and is initiated by the 
binding of chemoattractants or other pro-migratory ligands to cell surface receptors. 
Binding of ligands induces cell-signalling cascades, which influences gene transcription 
and cytoskeletal dynamics. At the leading edge of the cell during migration, actin is 
polymerized and stabilized by localized activity of multiple actin binding proteins 
including WASP and ARP2/3. Actin polymerization drives membrane extensions from 
the cell surface, called filipodia or lamellipodia, which contact and bind to the ECM 
using specific integrins to form focal adhesions. Actin and myosin contract to drive the 
cell body forward along ECM substrates, while the trailing edge of cells detaches from 
the ECM (Friedl and Wolf, 2003). 
In order to move through ECM barriers, a migrating cell must also be capable of ECM 
degradation. It is well documented that MT1-MMP localizes to the leading edge of cells, 
where it is presumed to promote matrix cleavage directly and indirectly at the cell-ECM 
interphase (Mori et al., 2002). Direct cleavage of laminin-5 by MT1-MMP in numerous 
cell types has been shown to promote cell migration. Additionally, CD44 and MT1-MMP 
co-localize within lamellipodia of migrating cells, whereby cleavage and subsequent 
shedding of CD44 initiated by MT1-MMP, promotes cell migration (Itoh, et al., 2006; 
Koshikawa et al., 2000, Ueda et al., 2003). In invasive cells, specific degradative cellular 
structures form that are rich in MT1-MMP. While structurally similar to filipodia and 
lamellipodia in migration, these structures are called podosomes in physiological cells 
and invadapodia if formed in cancer cells (Alblazi and Siar, 2015). The formation of 
invadapodia occurs on the basal side of a cell, whereby membrane protrusions are formed 
by actin polymerization, followed by shuttling of MT1-MMP to the distal ends (Artym, 
2006). This formation relies on hundreds of individual proteins that regulate the initiation 
and regulation of actin dynamics, vesicular transport, and cellular adhesion (Alblazi and 
Siar, 2015). While the fundamental organization of invadapodia can still form in the 
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absence of MT1-MMP, the resulting structures are non-functional and do not degrade 
ECM substrates (Buccione et al., 2009; Itoh et al., 2006).  
It is hypothesized that soluble pro-MMPs such as the gelatinases, are transported in 
vesicles destined for cell surface protrusions such as invadapodia (Itoh et al., 2006). In 
addition to direct ECM proteolysis, localized MT1-MMP activates pro-MMP-2, by which 
active MMP-2 can activate pro-MMP-9, to further potentiate ECM degradation 
(Khasigov et al., 2003). Cell protrusion localized MT1-MMP can also non-proteolytically 
initiate the MAPK pathway at the distal ends. Phosphorylated ERK1/2 is involved in both 
migration and invasion through phosphorylation and activation of cytoskeletal proteins. 
For example, phospho-ERK1/2 positively regulates the filamentous F-actin regulatory 
protein, cortactin. Cortactin plays an important role in tumour cell movement and 
invasion, as cortactin stabilizes ARP2/3 mediated actin networks (Kelley et al., 2011). 
Additionally, phospho-ERK1/2 activates the cells’ motility machinery by enhancing 
myosin light-chain kinase (MLCK) activity leading to increased myosin light chain 
(MLC) phosphorylation, allowing for myosin to bind actin filaments and resultantly 
contract to allow for cell movement (Reddy et al., 2003).  
Collectively, MT1-MMP localized during migration and invasion to cell specific motility 
structures, orchestrates both proteolytic and non-proteolytic cell functions necessary to 
promote both ECM degradation and movement along ECM substrates.   
1.7 Development of Synthetic MMP Inhibitors as Cancer 
Therapeutics 
Within distinct cancer types, diverse MMP family members are upregulated resulting in 
abnormal ECM remodeling, making MMPs an ideal target for therapeutic treatments. 
Many different MMP inhibitors (MMPIs) have been designed to target MMPs in cancer 
and although these compounds differ in their inhibitory potencies towards MMPs, none 
of them are selective for individual MMPs (including the gelatinases). The first 
generation of MMPIs were peptidomimetics (such as batimastat and marimastat) that 
mimicked the structure of collagen. They acted as competitive inhibitors and chelated the 
zinc ion present at the MMP's active site. To improve specificity, non-peptidomimetics 
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were synthesized on the basis of the MMP active site's three-dimensional conformation. 
Other MMPIs included tetracycline derivatives that inhibited both the MMPs' enzymatic 
activity and their synthesis (by blocking gene transcription) (Cathcart et al., 2015).  
To date, all clinical trials of these MMPIs in advanced cancer patients have failed. There 
are several possible reasons for the failure of MMPIs in the clinic such as dose limiting 
toxicity to surrounding healthy cells, interference with non-targeted cell signalling 
pathways, and structural similarity among the MMPs' catalytic domains. Moreover, the 
role of MMPs in cancer progression is not restricted to ECM-degrading activity, as 
various MMPs are also involved in, and influenced by, different signalling pathways that 
additionally impact tumour cell behaviour (López-Otín and Matrisian, 2007). All clinical 
trials regarding MMPs have converged upon the same problems, difficulty in designing 
MMPIs or cell signalling pathway targets with high selectivity. This project investigates 
the broad cellular function consequences of using non-selective inhibitors. 
1.8 Hypothesis and Objectives  
The presence and activation of both gelatinases (MMP-2 and MMP-9) within the ECM is 
heavily influenced by the abundance of active MT1-MMP present on the cell surface, 
while intracellular signalling pathways, such as the MAPK pathway, influence MMP-2 
and MMP-9 transcription factor activity and govern the availability of secreted gelatinase 
MMPs. In order to achieve proper cell function, the amount of active MT1-MMP, 
phosphorylated ERK1/2, and MMP-2 and -9 expression must be tightly regulated, as 
imbalance can result in aberrant ECM remodeling allowing for increased cell migration 
and invasion among other irregular cell functions.  
I hypothesized that the levels of phosphorylated ERK1/2 will be directly 
proportional to the levels of active MT1- MMP, and be correlated with increased 
gelatinase (MMP-2 and -9) MMP mRNA levels and increased invasive potential of 
breast cancer cells. 
Using MCF-7 (MT1-MMP and phospho-ERK1/2 deficient), MCF-7 MT1-MMP C2 
(predominately active MT1-MMP, high phospho-ERK1/2), MDA-MB-231 (High active 
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MT1-MMP, constitutive phospho-ERK1/2, high gelatinase MMP expression), and 231-
PDX (high pro and active MT1-MMP, high phosphoERK1/2) breast cancer cell lines 
(Table 1 and 2), this study was conducted to examine how altering ERK1/2 
phosphorylation, MMP catalytic activity, and MT1-MMP activation, affects MMP-2 and 
MMP-9 expression and subsequent breast cancer cell migration and invasion.  
The above breast cancer cell lines were treated with U0126, a MEK1/2 kinase inhibitor, 
BB-94, a pan-MMP catalytic site inhibitor, and Furin Inhibitor I targeting MT1-MMP 
activation. Each treatment was used to observe how changes to the MT1-MMP, phospho-
ERK1/2, gelatinase relationship influenced: 1) MT1-MMP and phospho-ERK1/2 protein 
levels, 2) changes in MT1-MMP, MMP-2, MMP-9, TIMP-2 mRNA levels, 3) 
transcription factor availability, 4) cell migratory and invasive potential, 5) cellular 3D 
morphology, and 6) ability of breast cancer cells to form vascularized tumours within 
chicken embryos. My Master’s research has taken an approach of selective removal of 
key players involved in breast cancer cell invasion in order to better understand each 
parts necessity in promoting this phenotype. 
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Table 1. A comparison of the relative levels of MT1-MMP and phospho-ERK1/2 
protein, gelatinase expression, and invasive potential of MCF-7, MCF-7 MT1-MMP 
C2, MDA-MB-231, and 231-PDX breast cancer cells. 
 
 
 
 
 
 
 MT1-MMP 
protein 
MMP-2 
expression 
MMP-9 
expression 
Phospho-
ERK1/2 
Invasive 
Potential 
MCF-7 + + + + + (Cepeda et al., 
2016) 
MCF-7 
MT1-MMP 
C2 
+++++++++ +++ +++++ +++++ ++ (Cepeda et al., 
2016) 
MDA-MB-
231 
++++ ++++++ +++++++ +++++++ ++++++ 
231-PDX ++++++ ++++ +++++++++ ++++++++ +++++ 
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Table 2. Origin, classification, and key characteristics of MCF-7 and MDA-MB-231 breast cancer cell lines.  
 MCF-7 cells are less invasive compared to MDA-MB-231 cells. The presence or absence of ER (estrogen receptor), PR (progesterone 
receptor), or HER2 (human epidermal growth factor receptor 2) receptors is indicative of how well cells respond to endocrine signals 
and chemotherapy treatment. Ki67 is a marker for cell proliferation; during interphase Ki67 is exclusively present within the nucleus. 
Ki67 protein is present during all active phases of the cell cycle (G1, S, G2, and mitosis), but is absent from resting cells (G0). Adapted 
from Holliday and Speirs 2011.  
 
 Tumour 
Source 
Pathology Organism Classification Immunoprofile Other Characteristics 
MCF-7 Metastasis; 
pleural 
effusion  
Adenocarcinoma Human Luminal A ER
+
, PR
+/-
, HER2
-
 Ki67 low, endocrine 
responsive, often 
chemotherapy responsive, 
invasive potential (+) 
MDA-
MB-231 
Metastasis; 
pleural 
effusion  
Adenocarcinoma Human Claudin-low/ 
triple negative 
ER
-
, PR
-
, HER2
-
 Ki67 high, low E-cadherin, 
claudin-3, claudin -4, and 
claudin 7, intermediate 
response to chemotherapy, 
invasive potential (++++++) 
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Chapter 2  
2 Material and Methods 
2.1 Cell Culture Conditions 
Human adenocarcinoma breast cancer cell lines MCF-7 (ATCC
®
 HTB-22
™
) and MDA-
MB-231 (ATCC
®
 HTB-26
™
) were generously donated by Dr. Lynne-Marie Postovit, 
University of Alberta.  
Three MCF-7 breast cancer cell lines that overexpress MT1-MMP were generated by PhD 
candidate Mario Cepeda, Western University. MCF-7 MT1-MMP C1, expressed ~2,500 
fold increase in MT1-MMP mRNA compared to MCF-7 parental cells, MCF-7 MT1-
MMP C2 showed a  ~1,100 fold increase, and MCF-7 MT1-MMP C3 had the lowest with 
an ~11 fold increase. These lines will be called MCF-7 C1, C2 and C3. Additionally, 
three MDA-MB-231 breast cancer cell lines were generated by Mario Cepeda that 
overexpress MT1-MMP. MDA-MB-231 MT1-MMP C1, expressed ~10 fold increase in 
MT1-MMP mRNA compared to MDA-MB-231 parental cells, MDA-MB-231 MT1-
MMP C2 showed a ~7 fold increase, and MDA-MB-231 MT1-MMP C3 had a ~2 fold 
increase. These lines will be referred to as MDA-MB-231 C1, C2, and C3. For relative 
comparison, MDA-MB-231 cells express ~175 fold more MT1-MMP mRNA compared 
to MCF-7 cells. Each stable cell line was characterized according to their levels of pro- 
and active MT1-MMP, expression of other ECM remodeling proteins, as well as their 
cellular movements in 2D and 3D space (Cepeda et al., 2016). 
Cells were cultured in Dulbecco’s Modified Eagles (DMEM)/F-12 medium (Thermo 
Fisher) supplemented with 10% fetal bovine serum (FBS), 100 IU/mL penicillin, 100 
μg/mL streptomycin, in a humidified incubator at 37°C and 5% CO2. Cells were 
maintained under 80% confluency and passaged accordingly using 0.25% Trypsin-EDTA 
(Thermo Fisher).  
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2.2 Generation of 231-PDX Stable Cell Line 
Additionally, to observe changes in cell behaviour following alteration to MT1-MMP 
activation, cellular expression of α1-PDX was used to block furin dependent processing 
of protein precursors. The Alpha1-Antitrypsin Portland, α1-PDX cDNA, contained within 
the mammalian expression pRc/CMV vector (Thermo Fisher), was obtained by generous 
donation from Dr. Gary Thomas, University of Pittsburgh (Pittsburgh, PA).  
MDA-MB-231 breast cancer cells were seeded at a density of 5x10
5
 cells/mL in a 35 mm 
cell culture dish (Corning) and incubated for 24 hours. Following incubation, cells were 
transfected with α1-PDX pRc/CMV vector, which contains a neomycin selection marker, 
using OPTI-MEM (Gibco) reduced serum medium and Lipofectamine 2000 (Thermo 
Fisher) according to the manufacturer’s instructions. Following transfection, cells were 
split 1:1000 and incubated in DMEM/FBS medium containing 1 mg/mL neomycin 
analog G418 (VWR). Individual colonies were selected after four weeks of incubation in 
selection medium and expanded to assay for alpha1-Antitrypsin Portland (α1-PDX) 
expression by qPCR and changes in MT1-MMP protein forms (pro- and active) via 
western blot analysis.  
2.3 Generation of MDA-MB-231 and 231-PDX ZsGreen 
Stable Cell Lines 
To identify MDA-MB-231 and 231-PDX cells injected into wounded vasculature of 
avian embryo CAM, ZsGreen fluorescent stable cell lines were generated. MDA-MB-231 
breast cancer cells and 231-PDX stable cells were subjected to viral transfection with 
cDNA encoding ZsGreen, a cytoplasmic-localized fluorescent protein, to generate the 
respective stably expressing ZsGreen lines ZsMDA-MB-231 and Zs231-PDX. This 
procedure was generously performed by personnel in the laboratory of Dr. Hon Leong, 
Lawson Health Research. In brief, cells were treated with a lentivirus containing ZsGreen 
in polybrene, a reagent that aids in viral transfection. One-day post transfection cells were 
treated with selection agent, puromycin (2 μL/mL), which was replenished for three days. 
Successful stable transfection was determined using fluorescence microscopy. These cell 
lines were used exclusively in the avian embryo  
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Table 3. Select chemical inhibitors used to treat MCF-7 and MDA-MB-231 cells, 
targeting ERK1/2 phosphorylation, MMP catalytic activity and MT1-MMP 
activation. 
 
 Treatment 
U0126 BB-94 Furin Inhibitor I 
Action 
 Targets MEK1 and 
MEK2 directly by 
inhibiting catalytic 
activity of active 
MEK1/2  
 Prevents 
phosphorylation of 
ERK1 and ERK 2 
 Inhibition is 
noncompetitive 
with respect to 
ERK and ATP 
substrates (DeSilva 
et al., 1998) 
 Broad spectrum 
MMP inhibitor 
 Competitive 
inhibition 
 Substrate analog 
binds to the zinc 
ion in MMP 
catalytic site (Low 
et al., 1996) 
 
 Competitive 
inhibitor of pro-
protein convertase 
(furin) 
 Binds catalytic site 
of furin, blocking 
activity (Coppola 
et al., 2008) 
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Table 4. Primer sequences used for qPCR. 
 
 
 
 Forward Reverse 
MT1-MMP 5’-GCAGAAGTTTTACGGCTTGCA-3’ 5’- TCGAACATTGGCCTTGATCTC-3’ 
MMP-2 5’- AGCTCCCGGAAAAGATTGATG-3’ 5’-CAGGGTGCTGGCTGAGTAGAT-3’ 
MMP-9 5’-CCTGGAGACCTGAGAACCAATC-3’ 5’-GATTTCGACTCTCCACGCATCT-3’ 
TIMP-2 5’-‘CGACATTTATGGCAACCCTATC-3’ 5’-GCCGTGTAGATAAACTCTATATCC-3’ 
α1-PDX 5’-TGAAATCCTGGAGGGCCTGA-3’ 5’-AACCAGCCAGACAGCCAGCT-3’ 
GAPDH 5’-ACCCACTCCTCCACCTTTGA-3’ 5’-CTGTTGCTGTAGCCAAATTCGT-3’ 
22 
 
tumour assay. 
2.4 Chemical Inhibitors 
The following inhibitors were used: BB-94 (Batimastat; Santa Cruz Biotechnology), 
U0126 (Santa Cruz Biotechnology), and Furin Inhibitor I (Millipore; Table 3).  Dosages 
of respective inhibitors were determined using cell viability assays performed in the 
Damjanovski laboratory, and are as follows: U0126 10 μM, BB-94 10 μM, and Furin 
Inhibitor I 5 μM, 10 μM, 20 μM.  
2.5 RNA Extraction and Quantitative real-time PCR 
Cells were seeded at a density of 1x10
6 
cells/mL in 35 mm cell culture plates (Corning) in 
2 mL of DMEM/FBS medium and were treated with U0126 (10 μM), BB-94 (10 μM), 
Furin inhibitor I (5, 10, 20 μM), or DMSO (0.1%) for 24 hours, lysed, RNA was 
collected using the RNeasy Kit (Qiagen). cDNA was synthesized from 1 μg of RNA 
using qScript cDNA supermix (Quanta). The relative mRNA levels of MT1-MMP, MMP-
2, MMP-9, alpha1-Antitrypsin Portland (α1-PDX), and TIMP-2 (Table 4) were assayed 
by qPCR using SensiFAST SYBR No-ROX Kit (FroggaBio) and the CFX Connect™ 
Real-Time PCR Detection System (Bio-Rad). mRNA levels were quantified by the 
ΔΔCT method and displayed as fold change relative to MCF-7 or MDA-MB-231 breast 
cancer cells under normal culture conditions. The level of glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) mRNA was used as the internal control.  
2.6 Antibodies 
For immunoblot analysis, the following primary antibodies were used: Human MT1-
MMP (1:1000, AB6004, Millipore), Phospho-ERK1/2 (phospho-ERK1/2) (1:2000, 
D13.14.4E), Total ERK1/2 (1:2000, 137F5) (Cell Signalling Technology), and β-Actin 
(1:1000, C4). Goat anti-mouse IgG (H+L) (Bio-Rad) and goat anti-rabbit IgG (H+L) 
(Thermo Fisher) HRP conjugates were used as secondary antibodies (1:10000).  
2.7 Protein Collection and Immunoblotting 
Cells were seeded at a density of 1x10
6 
cells/mL in 35 mm culture plates (Corning) in 2 
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mL of DMEM/FBS medium and treated with U0126 (10 μM), BB94 (10 μM), Furin 
inhibitor I (5, 10, 20 μM), or DMSO (0.1%) for 24 hours. Post-incubation cells were 
washed with PBS (pH=7.2) and disrupted using lysis buffer (150 mM NaCl, 1% NP-40, 
0.5% NaDC, 0.1% SDS, 50 mM Tris pH 8.0) supplemented with protease/phosphotase 
inhibitor (Thermo Scientific). Cell lysates were incubated on ice for 20 minutes and 
homogenized by sonication (Misonix Ultrasonic Liquid Processors XL-2000 Series). 
Total protein concentration was determined by Pierce BCA Protein Assay Kit (Thermo 
Fisher) performed as per manufacturer’s instructions and absorbance was measured at 
595 nm by the Microplate Reader Model 3550-UV (BioRad). Protein aliquots (15 μg) 
were analyzed by immunoblotting with MT1-MMP, β-actin, phospho-ERK1/2 or total 
ERK1/2 primary antibodies, followed by incubation with the appropriate secondary HRP-
conjugated antibody and detected using SuperSignal West Pico chemiluminescent 
substrate (Thermo Fisher). Blots were blocked using either 0.5% BSA or 5% BSA in 
TBST, as directed by the primary antibody manufacturer, and probed using the 
appropriate primary antibodies. Incubation with primary antibodies occurred overnight at 
4°C, and secondary antibodies for one hour at room temperature. Images were captured 
using the Molecular Imager
®
 ChemiDoc
TM
 XRS System (BioRad) and blots were 
analyzed using QuantityOne 1-D analysis software. 
2.8 Generation of MMP-2 Conditioned Medium for Cell 
Culture Treatment 
MMP-2 conditioned medium was provided by PhD candidate, Mario Cepeda, Western 
University, and used to verify the efficiency of BB-94 in preventing substrate cleavage 
activity of MMPs as determined by gelatin zymography analysis  In brief, conditioned 
medium (CM) containing high levels of MMP-2 protein was created by transfecting 
MCF-7 breast cancer cells with a cDNA construct coding for pro-MMP-2 protein. 
Following a 24-hour incubation period, pro-MMP-2 transfected MCF-7 cells were 
washed with phosphate buffered saline (PBS) and incubated in DMEM/F12 medium void 
of FBS for 24 hours. This serum-free medium conditioned with the soluble pro-MMP-2 
transfection product was then collected, aliquoted, and stored at -80°C for later use.  
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2.9 Gelatin Zymography and Reverse Gelatin Zymography 
Gelatin zymography was performed as previously described (Toth et al., 2001) to 
compare the levels of secreted pro- and activated MMP-2 and MMP-9 in the medium of 
MCF-7, MCF-7 MT1-MMP C2, and MDA-MB-231 cells following treatment with 
DMSO (0.1%), U0126 (10 μM), or BB-94 (10 μM). Briefly, 15 μL of medium collected 
from treated cells were loaded to a 10% polyacrylamide-0.1% gelatin gel and subjected to 
electrophoresis. After electrophoresis, the gels were incubated in renaturing buffer (25% 
v/v Triton X-100 in dH2O) to ensure MMP functional ability, and then incubated in 
developing buffer (0.5 M Tris–HCl, pH 7.8, 2 M NaCl, 0.05 M CaCl2, and 0.2% Brij 35) 
at 37°C for 48 hours to allow the MMPs to cleave the gelatin embedded within the 
polyacrylamide gel. After the incubation period, the gel was stained with a 0.5% 
Coomassie blue, 5% methanol, 10% acetic acid solution. The gel was then progressively 
destained with a 20% methanol, 10% acetic acid solution until bands that represent 
cleaved gelatin were clearly visible. Images were taken using the Molecular Imager
®
 
ChemiDoc
TM
 XRS System (BioRad).  
Reverse zymography, which measured TIMP activity, was performed by adding MMP 
conditioned medium to the 10% polyacrylamine-0.1% gelatin gel lacking denaturing 
detergents. Conditioned medium was obtained by incubating HS578t breast cancer cells 
in serum-free medium for 24 hours, as these cells naturally express high levels of MMP-2 
(Takahashi et al., 1999). Samples subjected to gelatin zymography were additionally 
subjected to reverse gelatin zymography. Protein loading, renaturing, and staining 
processed are identical to gelatin zymography analysis, however in reverse zymography 
when the gel is destained it will remain clear, while dark blue banding represents TIMP 
proteins bound to MMPs embedded in the polyacrylamide gel. 
2.10  Firefly Luciferase Transcriptional Activity Assay 
Transcriptional activity of AP-1 and NF-κB, MT1-MMP and MMP-9 specific 
transcription factors, was examined in MCF-7, MCF-7 MT1-MMP C2, MDA-MB 231, 
and 231-PDX cells following respective inhibitor treatment. In brief, cells were seeded at 
a density of 3.0 x10
4
 cells/well in a 96-well culture plate (Corning) and incubated for 24 
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hours. Following incubation, cells were transfected with Lipofectamine 2000 (Thermo 
Fisher) according to the manufacturer’s instructions and OPTI-MEM (Gibco) reduced 
serum medium, in combination with 0.2 μg of mammalian 3xAP1pGL3 (Plasmid # 
40342) (Transcription factor: AP-1) or p1242 3xKB-L (Plasmid #26699) (Transcription 
factor: NF-κB) luciferase plasmids (Addgene). 24 hours post transfection, MCF-7, MCF-
7 MT1-MMP C2, and MDA-MB-231 cells were subjected to treatment with DMSO 
(0.1%), U0126 (10 μM), or BB-94 (10 μM). 12 hours later cells were lysed and treated 
with Firefly Luciferase Glow Assay reagents (Thermo Fisher) according to the 
manufacturer’s instructions. Luminescence was detected using ModulusTM II Microplate 
Multimode Reader and the GloMax
®
- Multi Detection System with Instinct
®
 Software.  
2.11  Scratch Wound Closure Migration Assay 
To examine the effects of respective inhibitor treatment on cell migratory potential, 
MDA-MB-231 breast cancer cells were seeded at a density of 2.5x10
5
 cells/mL in a 35 
mm cell culture dish (Corning) in 2 mL of DMEM/FBS medium and allowed to form a 
monolayer for 24 hours. Following incubation, medium was aspirated and the monolayer 
was disrupted using a 1000 μL pipette tip to create a wound down the length of the 
culture dish. The remaining adhered cells were washed three times with PBS (pH 7.2) to 
remove cell debris and then incubated with fresh DMEM 10% FBS, 1% pen/strep 
medium containing treatment of DMSO (0.1%), U0126 (10 μM), BB-94 (10 μM), or 
Furin Inhibitor I (20 μM). 2 hours post wound generation, using the Zeiss Observer.A1 
AX10 microscope, 10 images were captured down the length of the scratch that represent 
the ‘initial’ size of the wound for each respective sample. The same area of the wound 
was imaged at 6, 12, and 24 hours following wound healing to examine the ability to 
migrate into the wound space. Scratch closure was quantified by measuring the width of 
the scratch each day and normalizing it to the initial size of the scratch. Scratch closure is 
presented as a mean percentage of the initial scratch size ± SEM.  
2.12  Transwell Cell Motility Assays 
The migratory and invasive potential of MDA-MB-231 cells was measured using 24-well 
8 μm pore transwell inserts (Corning). 2.0 x 104 cells were seeded on the upper chamber 
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of the transwell in serum-free medium treated with DMSO (0.1%), U0126 (10 μM), or 
BB-94 (10 μM). Treated cells were allowed to migrate (24 hours) or invade (48 hours) 
towards the bottom chamber which was placed in DMEM/F-12 medium supplemented 
with 10% FBS and 1% pen/strep, serving as the chemoattractant. Migration assays were 
performed with uncoated transwell inserts, whereas invasion assays were performed with 
inserts coated with 20% Matrigel, a basement membrane analog. 20% Matrigel was 
generated by diluting Matrigel (BD Biosciences) in DMEM/F-12 serum-free medium. 
Cells that migrated to the lower chamber of the transwell insert were fixed, stained, and 
quantified as per Marshall, 2011. To quantify cell migration, cells were fixed in 100% 
methanol, and non- motile cells remaining in the upper surface of the transwell removed 
with a damp cotton swab. Cells on the bottom of transwells were stained using a 0.5% 
solution of crystal violet in distilled water. These stained transwells were then 
individually destained in 33% acetic acid, and the absorbance of this solution at 490 nm 
was quantified using the Microplate Reader Model 3550-UV (BioRad) as a correlative 
measurement of cell number. Invasion transwells, were fixed with 100% methanol and 
cells that did not invade through the transwell insert and residual Matrigel were removed 
from the upper membrane surface with a damp cotton swab. Invading cells were then 
stained with a 0.5% crystal violet solution and residual stain was removed using a cotton 
swab. Invasion transwells were imaged using the Leica DM16000 B microscope with 
Hamamatsu camera controller (C10600) at 20X magnification. 15 images were taken per 
transwell and were blindly quantified using ImageJ software (U.S. National Institutes of 
Health, Bethesda, Maryland, USA).  
2.13  Three Dimensional (3D) Cell Culture 
MDA-MB-231 and 231-PDX cells were embedded in 50% Matrigel matrix (BD 
Biosciences) and processed for fluorescent staining to assess changes in invasive 
morphological features as described by Cvetković, et al., 2014. 35 mm Glass-bottom cell 
culture dishes (MatTek) were prepared by coating the glass with 50% Matrigel (BD 
Bioscience) in serum-free medium, allowing the matrix to solidify, and seeding 2.5x10
4 
cells in 50% Matrigel in serum-free medium above this layer to result in cells completely 
suspended in matrix. DMEM/F-12 serum-free medium combined to generate 50% 
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Matrigel and DMEM/F-12 medium supplemented with 10% FBS and 1% pen/strep were 
treated with DMSO (0.1%), U0126 (10 μM), or BB-94 (10 μM).  
Fluorescent staining procedure was done as described in Cvetković, et al., (2014) using 
Alexa Fluor 633 phalloidin (1:100) and DAPI (1 ug/mL) staining. Cell colony 
morphology was monitored for five days using bright-field microscopy (Leica DM16000 
B microscope with Leica DFC425 camera) at 10X magnification, and representative 50 
μm z-stack images (2 μm interval) taken at random locations across the matrix were 
captured using Leica MMAF software (Metamorph®). After five days, cells within the 
matrix were fixed using 20% acetone, 80% methanol and prepared for fluorescent 
staining using  Alexa Fluor 633 phalloidin (Thermo Fisher, 1:100), and DAPI (1 μL/mL, 
BioShop Canada) to examine F-actin and nuclei, respectively. Prepared samples were 
imaged using a Nikon A1R+ confocal microscope and NIS Elements software (Nikon), 
capturing Z-stacks of approximately 100 μm. 
To analyze and score morphology of cell colonies, images representing a field of view at 
20x magnification, were blindly analyzed using ImageJ software (U. S. National 
Institutes of Health, Bethesda, Maryland, USA). Protrusions were defined as thin 
extensions that emanated from a round cell colony. The number of protrusions on all cell 
colonies in an image was counted, with longer protrusions counted as multiples of the 
average protrusion length seen in that image to adjust for the heterogeneity in size 
observed. Disseminations were identified as small, round cells immediately adjacent to a 
larger colony. The score, representing the total number of protrusions or total number of 
disseminations for each treatment, was divided by the total number of colonies to arrive 
at the final measurement of protrusions or disseminations per colony. 
2.14  Avian Embryo Tumour Vascularization Assay 
The vascularization of artificial Matrigel tumours of ZsGreen tagged MDA-MB-231 cells 
(ZsMDA-MB-231) treated with DMSO (0.1%), U0126 (10 μM), or BB-94 (10 μM), and 
ZsGreen tagged 231-PDX cells (Zs231-PDX) in Matrigel (BD Bioscience) was assessed 
in avian embryos following the technique developed by Dr. Hon Leong, Lawson Health 
Sciences, Western University. Avian embryos, materials, equipment, and facilities were 
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generously provided by Dr. Hon Leong, Lawson Health Research Institute, London 
Ontario. Chick embryos were incubated in culture boats for nine days at 37°C in a 
humidified chamber. A superficial wound was introduced to the vasculature of the 
chorioallantoic membrane (CAM) of embryos and an artificial tumour composed of 10 
μL of Matrigel (BD Bioscience) containing ~500 000 cells was injected into the wound. 
Embryos were incubated for a further eight days, during which appropriate inhibitor 
treatments were applied every 48 hours directly on top of the tumour using a 10 μL 
pipette within the wounded CAM vasculature. Tumours were then examined using 
fluorescent stereomicroscopy to assess if vasculature had developed at the tumour site. 
Vascularization was determined to have occurred if the wound site showed capillaries 
associated with a tumour, which had successfully grown beneath the CAM layer. This 
was accomplished by comparing observed vasculature using bright field microscopy to 
areas of contrast observed under fluorescent conditions. Vascularization was quantified 
as a binary measurement, indicated by the presence or absence of tumour-localized 
vasculature in individual embryos. Degree of wound closure was also used as a measure 
of tumor invasion, whereby wound closure was characterized as the presence of the 
tumor completely under the CAM and regression of initially wounded vasculature.  
2.15  Densitometry Analysis 
Quantitative densitometric analysis of immunoblots was performed using QuantityOne 
software (Bio-Rad). Band intensity was obtained for the MT1-MMP, β-Actin, phospho-
ERK and total ERK1/2 signal of each sample from three independent biological 
experiments. MT1-MMP pro- and active protein is presented as a ratio between each 
respective band intensity and β-Actin signal. ERK1/2 activation is presented as a ratio 
between phospho-ERK1/2 and total ERK1/2 band intensity normalized to MCF-7 or 
MDA-MB-231 cells under control conditions.  
2.16  Statistical Analysis 
Statistical analysis and graphing was performed using GraphPad Prism version 6.0 
(GraphPad software, La Jolla, CA, USA). Data is presented as mean ± SEM, where all 
experiments were comprised of at least 3 biological replicates. One-way and Two-way 
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ANOVA followed by Tukey’s, Dunnett’s, or Sadik’s post-hoc tests or students t-test were 
used and are indicated respectively in each figure legend. Different levels of statistical 
significance are denoted by a different number of asterisks and are as follows: ****, p ≤ 
0.0001, ***, p ≤ 0.001, **, p ≤ 0.01, *, p ≤ 0.05, ns, p < 0.05. 
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Chapter 3  
3 Results  
3.1 MEK1/2 inhibitor altered MMP-2 and MMP-9 mRNA 
levels in MCF-7 MT1-MMP C2 and MDA-MB-231 cells 
Overexpression of MT1-MMP in MCF-7 cells (MCF-7 MT1-MMP C1, C2, and C3) 
resulted in higher levels of phosphorylated ERK1/2 compared to MCF-7 parental cells. 
MCF-7 C2 cells notably contained the highest levels of phospho-ERK1/2 and were thus 
chosen for further investigation. In addition to showing the highest phospho-ERK1/2 
levels, these MCF-7 C2 cells were the only cell line exhibiting MT1-MMP protein 
predominately in its active form (Cepeda et al., 2016), and also had the highest 
expression of MMP-2 and MMP-9. When each MCF-7 cell line was treated with the 
MEK1/2 inhibitor, U0126, ERK1/2 phosphorylation was consistently decreased in each 
cell line (Fig. 2a). In addition, treatment of MCF-7 C2 cells with the MEK1/2 inhibitor 
resulted in a prominent inverse relationship between MMP-2 and MMP-9 mRNA levels, 
with a significant (p ≤ 0.01) ~1.6 fold increase in MMP-2 and a significant (p ≤ 0.01) 
~7.5 fold decrease in MMP-9, respectively (Fig. 2b). These results indicated that 
inhibiting ERK1/2 phosphorylation in cells with predominately active MT1-MMP 
protein, expression of MMP-9 was impacted more greatly than expression of MMP-2. 
While MCF-7 C2 cells provide a model demonstrating the impact of artificially elevated 
levels of active MT1-MMP protein on phospho-ERK1/2, and MMP-2 and -9 expression, 
MDA-MB-231 breast cancer cells naturally posses high basal levels of active MT1-
MMP, phospho-ERK1/2, and increased MMP-2/-9 expression (Cepeda et al., 2016), and 
are thus a target for comparison. To determine if the relationship between phospho-
ERK1/2 and MMP-2 and -9 mRNA levels is conserved between breast cancer cells 
MDA-MB-231 cells were treated with the MEK1/2 inhibitor. Treatment of MDA-MB-
231 cells with 10 μM of U0126 (Fig. 3a) resulted in a significant (p ≤ 0.0001) decrease in 
ERK1/2 phosphorylation (~10.9 fold difference), but negligible changes were observed in 
the levels of pro- and active forms of MT1-MMP (p > 0.05) (Fig. 3b). Nonetheless, MT1- 
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Figure 2. Phosphorylated ERK1/2 mediates an inverse relationship between MMP-2 
and MMP-9 gene expression in MCF-7 breast cancer cells. 
(a)Western blot analysis showing levels of phosphorylated ERK1/2 protein in MCF-7 
breast cancer cells and three clonally selected MCF-7 cell lines that stably express 
different levels of MT1-MMP, treated with MEK1/2 inhibitor (U0126 10 μM) or vehicle 
control (DMSO 0.1%). Total ERK1/2 was used as a loading control. MCF-7 MT1-MMP 
C2 cells exhibited the highest levels of phospho-ERK1/2, however all cell lines 
demonstrated a decrease in phosphorylated ERK1/2 protein following treatment with 
U0126. (b) qPCR analysis of MMP-2 and MMP-9 mRNA in MCF-7 breast cancer cells 
and three clonally selected MCF-7 cell lines that stably express different levels of MT1-
MMP subjected to U0126 (10 μM) or DMSO (0.1%). Fold change was quantified using 
the ΔΔCT method and shown as mean ± SEM. One-way ANOVA followed by Tukey’s 
post-hoc test; **, p ≤ 0.01, ns, p > 0.05. MCF-7 C2 cells showed an inverse relationship 
between MMP-2 and MMP-9 mRNA levels, which significantly increased and decreased 
respectively, following treatment with U0126.  
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Figure 3. Phosphorylated ERK1/2 mediates an inverse relationship between MMP-2 
and MMP-9 gene expression in MDA-MB-231 breast cancer cells. 
(a) Western blot (top 4 panels), gelatin zymography (middle panels), and reverse gelatin 
zymography analysis (bottom panel) of MDA-MB-231 breast cancer cells subjected to 
MEK1/2 inhibitor (U0126 10 μM) or vehicle control (DMSO 0.1%) presenting ERK1/2 
phosphorylation, pro- and active MT1- MMP, pro-and active MMP-2 and -9, and TIMP-
2 protein levels, respectively. For western blot analysis, total ERK1/2 and β-actin served 
as loading controls. (b) Densitometry quantification of phospho-ERK1/2 protein 
measured in western blots, Student’s t-test; ****, p ≤ 0.0001, where U0126 was effective 
at decreasing ERK1/2 phosphorylation, however MT1-MMP pro- and active protein 
levels were unchanged, analyzed by two-way ANOVA followed by Tukey’s post hoc 
test; ns, p > 0.05. (c) qPCR analysis of MT1-MMP, MMP-2, MMP-9 , and TIMP-2 
mRNA isolated from MDA-MB-231 breast cancer cells treated with U0126 (10 μM) or 
DMSO (0.1%). Fold change was quantified using the ΔΔCT method and shown as mean 
± SEM, as analyzed by Student’s t-test; ****, p ≤ 0.0001, **, p ≤ 0.01, ns, p > 0.05. 
Following treatment with U0126, MDA-MB-231 cells showed a significant increase in 
MMP-2 mRNA levels and a significant decrease in MMP-9 mRNA levels, and therefore 
indicated that this MMP expression relationship was conserved between the MCF-7 
MT1-MMP C2 and MDA-MB-231 breast cancer cell lines. 
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MMP mRNA levels were significantly (p ≤ 0.01) decreased ~1.4 fold. Furthermore, 
treatment of MDA-MB-231 cells with U0126 (10 μM) resulted in a significant (p ≤ 
0.0001) ~4.4 fold increase in MMP-2 mRNA levels, but a significant (p ≤ 0.0001) ~5 fold 
decrease in MMP-9 mRNA levels, with no change (p > 0.05) in TIMP-2 mRNA (Fig. 3c), 
all of which are consistent with gelatin zymography analysis of these proteins (Fig. 3a). 
The consistency of the inverse relationship of increased MMP-2 mRNA and decreased 
MMP-9 mRNA following inhibition of ERK1/2 phosphorylation not only suggests how 
these gelatinases are regulated, but also that their regulation is conserved between breast 
cancer cell lines used.  
3.2 Inhibition of MT1-MMP catalytic site increased total 
MT1-MMP protein levels and altered subsequent MMP-
2 and MMP-9 mRNA levels in MCF-7 and MDA-MB-231 
breast cancer cells 
Gelatin zymography analysis of low MT1-MMP protein MCF-7 parental cells and high, 
predominately active MT1-MMP, MCF-7 C2 cells treated with the pan-MMP catalytic 
site inhibitor BB-94 showed the effect of MMP inhibition on pro-MMP-2 activation. 
Using gelatin zymography, MCF-7 C2 cells treated with pro-MMP-2 conditioned 
medium demonstrated a transition of pro-MMP-2 through its intermediate to active form 
(Fig. 4a, lane 3). Additionally, MCF-7 C2 cells treated with BB-94 lack active MMP-2 
(Fig. 4a, lane 4) and confirmed the efficiency of the BB-94 chemical inhibitor in 
preventing MMP catalytic site activity. BB-94 treatment to inhibit MT1-MMP catalytic 
activity was used along with MEK1/2 inhibitor, U0126, to further examine the regulation 
of MT1-MMP protein forms. 
Treatment of parental MCF-7 and MCF-7 C2 cells with DMSO (0.1%), U0126 (10 μM), 
and BB-94 (10 μM) changed the total amount of MT1-MMP protein present within 
MCF-7 C2 cells, with most prominent changes in the active form, as shown by western 
blot (Fig. 4b). Specifically, inhibition of ERK1/2 phosphorylation caused a significant (p 
≤ 0.0001) decrease in active MT1-MMP thus reducing the total amount of MT1-MMP  
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Figure 4. Inhibition of ERK1/2 phosphorylation and MT1-MMP catalytic site 
changes MT1-MMP pro- and active protein forms and associated MMP-2 and 
MMP-9 mRNA levels in MCF-7 MT1-MMP C2 cells.  
(a) Gelatin zymography analysis of MCF-7 and MCF-7 MT1-MMP C2 cells treated with 
pan-MMP catalytic site inhibitor BB-94 (10 μM) or vehicle control (DMSO 0.1%) and 
incubated for 12 hours with serum-free medium (control) or serum-free medium 
supplemented with conditioned medium (CM) containing pro-MMP-2. Only MCF-7 C2 
cells treated 0.1% DMSO and supplemented with CM containing pro-MMP-2 showed a 
transition of pro-MMP-2 through its intermediate and active forms, whereas application 
of BB-94 prevented pro-MMP-2 activation, and demonstrated the effectiveness of BB-94 
in inhibiting MMP catalytic activity. (b) Western blot analysis of MCF-7 and MCF-7 C2 
cells showing pro- and active MT1-MMP protein levels and ERK1/2 phosphorylation 
following treatment with DMSO (0.1%), U0126 (10 μM), or BB-94 (10 μM). β-actin and 
total ERK1/2 respectively serve as loading controls. (c) Densitometry quantification of 
western blotted MT1-MMP protein isoforms in MCF-7 C2 cells, Two-way ANOVA 
followed by Tukey’s post hoc test; ****, p ≤ 0.0001,*, p ≤ 0.05 and phospho-ERK1/2 
protein, Student’s t-test; ***, p ≤ 0.001, **, p ≤ 0.01. U0126 treated MCF-7 C2 cells 
exhibited less total MT1-MMP, therefore both decreased pro- and active forms, while 
MCF-7 C2 cells treated with BB-94 showed more total MT1-MMP, comprising of 
increased pro- and active forms. (d) qPCR analysis of MT1-MMP, MMP-2, and MMP-9 
mRNA from MCF-7 C2 cells treated with BB-94 (10 μM) or DMSO (0.1%). Fold change 
was quantified using the ΔΔCT method and shown as mean ± SEM. Student’s t-test; ***, 
p ≤ 0.001,**, p ≤ 0.01. An inverse, yet opposite relationship to that of U0126 treatment, 
between MMP-2 and MMP-9 mRNA levels following BB-94 treatment was observed, 
comprising of significantly decreased MMP-2 mRNA and significantly increased MMP-9 
mRNA. 
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protein compared to MCF-7 parental cells by ~75%. Inhibition of MT1-MMP catalytic 
activity significantly (p ≤ 0.0001) increased both active MT1-MMP and overall total 
MT1-MMP protein levels by ~69%. In addition, treatment of MCF-7 C2 cells with 
U0126 significantly (p ≤ 0.0001) reduced ERK1/2 phosphorylation, while treatment with 
BB-94 significantly (p ≤ 0.05) increased ERK1/2 phosphorylation (Fig. 4b lane 4, and c). 
As shown by qPCR, treatment of MCF-7 C2 cells with BB-94 significantly increased 
MT1-MMP ~1.8 fold (p ≤ 0.01) and MMP-9 mRNA levels ~1.6 fold (p ≤ 0.001), but 
significantly decreased MMP-2 mRNA ~0.1 fold (p ≤ 0.01) (Fig. 4d). BB-94 treatment 
altered MMP mRNA levels in an inverse manner (decreased MMP-2, increased MMP-9) 
when compared to that of U0126 treatment (increased MMP-2, and decreased MMP-9). 
In order to determine if this alteration of MMP-2 and MMP-9 mRNA levels upon BB-94 
treatment was breast cancer cell specific, MDA-MB-231 cells were also treated with 10 
μM of BB-94. MDA-MB-231 cells appeared more resistant to treatment, as MT1-MMP 
protein levels and ERK1/2 phosphorylation were not significantly (p > 0.05) changed 
(Fig. 5a and b). However, these BB-94 treated cells did exhibit changes in MT1-MMP 
and MMP-9 mRNA levels which were significantly increased ~1.8 fold (p ≤ 0.01) and 
~1.5 fold (p ≤ 0.05) respectively. Additionally MMP-2 mRNA levels were significantly 
decreased ~0.7 fold (p ≤ 0.01) (Fig. 5c). There is a consistent inverse relationship 
between the mRNA levels of the gelatinases when treated with BB-94. This inverse 
relationship, decreased MMP-2 and increased MMP-9 mRNA levels, following inhibition 
of MMP catalytic activity is conserved among breast cancer cell lines, and may provide 
insight as to how these gelatinases are regulated. 
3.3 Inhibiting pro-MT1-MMP activation changed MMP-2 
and MMP-9 mRNA levels and resulted in altered 
migratory and invasive potential in MCF-7 and MDA-
MB-231 breast cancer cells 
To determine the effects of reduced MT1-MMP active protein levels in influencing 
phosphorylation of ERK1/2, MCF-7 C2 cells which contain predominately active MT1-
MMP, were treated with increasing concentrations of protein convertase Furin inhibitor. 
(Fig. 6a). 24-hour treatment of MCF-7 C2 cells with 20 μM of Furin inhibitor I was  
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Figure 5. Inhibition of the MT1-MMP catalytic site does not changes MT1-MMP 
pro- and active protein forms, but does change MT1-MMP, MMP-2, and MMP-9 
mRNA levels in MDA-MB-231 breast cancer cells.  
(a) Western blot analysis showing pro- and active MT1-MMP protein and ERK1/2 
phosphorylation following treatment of MDA-MB-231 breast cancer cells with pan-
MMP catalytic site inhibitor BB-94 (10 μM) or vehicle control (DMSO 0.1%). β-actin 
and total ERK1/2 respectively serve as loading controls. (b) Densitometry quantification 
of western blotted MT1-MMP protein isoforms, Two-way ANOVA followed by Tukey’s 
post hoc test; ns, p > 0.05 and phospho-ERK1/2 protein, Student’s t-test; ns, p > 0.05. (c) 
qPCR analysis of MT1-MMP, MMP-2, MMP-9 , and TIMP-2 mRNA from MDA-MB-
231 cells treated with BB-94 (10 μM) or DMSO (0.1%). Fold change was quantified 
using the ΔΔCT method and shown as mean ± SEM and analyzed by Student’s t-test; **, 
p ≤ 0.01, *, p ≤ 0.5, ns, p > 0.05. An inverse, yet opposite relationship to that of U0126 
treatment, between MMP-2 and MMP-9 mRNA following BB-94 treatment was 
observed, comprising of significantly decreased MMP-2 mRNA levels and significantly 
increased MMP-9 mRNA levels. This observed relationship, decreased MMP-2 and 
increased MMP-9 mRNA levels, was conserved between MCF-7 MT1-MMP C2 and 
MDA-MB-231 breast cancer cell lines. 
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Figure 6. Inhibition of MT1-MMP activation reduces active MT1-MMP levels and 
ERK1/2 phosphorylation with subsequent changes MMP-2 and MMP-9 mRNA 
levels in MCF-7 MT1-MMP C2 cells.  
(a) Western blot analysis showing pro- and active MT1-MMP and phospho-ERK1/2 
protein levels following treatment of MCF-7 and MCF-7 MT1-MMP C2 cells with MT1-
MMP activation inhibitor, Furin Inhibitor I, at increasing concentrations (5, 10, 20 μM) 
or vehicle control (DMSO 0.1%). β-actin, and total ERK1/2 served as loading controls 
respectively. (b) Densitometry quantification of western blot analysis of MT1-MMP 
protein isoforms in MCF-7 C2 cells showed decreased levels of active MT1-MMP with 
increasing concentration of Furin Inhibitor I, as analyzed by two-way ANOVA followed 
by Sidak’s post hoc test; ***, p ≤ 0.001, **, p ≤ 0.01,*, p ≤ 0.05. Densitometry 
quantification of western blotted phospho-ERK1/2 protein showing decreased ERK1/2 
phosphorylation with increasing concentration of Furin Inhibitor I, as analyzed by one-
way ANOVA followed by Tukey’s post hoc test; ****, p ≤ 0.0001, ***, p ≤ 0.001,**, p 
≤ 0.01. (c) qPCR analysis of MMP-2 and MMP-9 mRNA in MCF-7 C2 cells subjected to 
increasing concentrations (5, 10, 20 μM) of Furin inhibitor I or DMSO (0.1%) exhibiting 
significantly increased MMP-2 mRNA levels and significantly decreased MMP-9 mRNA 
levels. Fold change was quantified using the ΔΔCT method and shown as mean ± SEM. 
One-way ANOVA followed by Dunnett’s post-hoc test; ****, p ≤ 0.0001,**, p ≤ 0.01, *, 
p ≤ 0.05.   
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determined to be the most effective in altering the forms of MT1-MMP (Fig. 6a, lane 8). 
This treatment caused an 11.9% significant (p ≤ 0.001) increase in pro-MT1-MMP 
protein levels, and 11.8% significant (p ≤ 0.01) decrease in active MT1-MMP protein 
levels. 20 μM of Furin inhibitor I also significantly (p ≤ 0.0001) reduced ERK1/2 
phosphorylation by 50% (Fig. 6b). Furthermore, this treatment resulted in ~0.8 fold 
significant (p ≤ 0.01) increase in MMP-2 and ~1.8 fold significant (p ≤ 0.0001) decrease 
in MMP-9 mRNA levels (Fig. 6c).  
Because 20 μM of Furin Inhibitor I successfully reduced active MT1-MMP and phospho-
ERK1/2 levels, and induced changes in gelatinase expression in MCF-7 C2 cells, MDA-
MB-231 cells were treated with the same concentration in order to determine if the furin 
inhibitor was capable of eliciting the same effect in cells which naturally contain higher 
levels of active MT1-MMP protein. Treatment of MDA-MB-231 cells with this inhibitor 
did not significantly (p > 0.05) change MT1-MMP protein forms, and did not effect 
ERK1/2 phosphorylation (Fig. 7a and b). However, this inhibitor changed MT1-MMP 
mRNA levels, as treated MDA-MB-231 cells displayed a significant (p ≤ 0.05) decrease 
in MT1-MMP (~0.22 fold) and MMP-9 (~0.2 fold) mRNA levels and a significant (p ≤ 
0.05) increase in MMP-2 mRNA (~0.9 fold) (Fig. 7c. The changes in MMP-2 and MMP-
9 mRNA levels in MDA-MB-231 cells following treatment with Furin inhibitor I were 
consistent with the changes observed in the MCF-7 C2 cells.  
As the use of chemical inhibitors is transient, to elucidate the effect of a more consistent 
alteration of furin function, MDA-MB-231 stable cell lines were generated expressing the 
alpha1-Antitrypsin Portland gene, α1-PDX (Fig. 8a). The alpha1-Antitrypsin Portland 
gene contains an R-X-X-R conserved sequence, which similarly to Furin Inhibitor I, 
targets the activation site of furin (Thomas, 2002) inhibiting its protein convertase 
activity. These 231-PDX stable cells contained overall higher levels of total MT1-MMP 
protein, and while they contained significantly (p ≤ 0.01) increased (~6 fold) levels of 
pro-MT1-MMP, they also contained significantly (p ≤ 0.001) increased (~3 fold) levels 
of active MT1-MMP (Fig. 8b and c). 231-PDX cells also had significantly (p ≤ 0.05) 
more phosphorylated ERK1/2 (Fig. 8b and c) and significantly increased mRNA levels of 
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MT1-MMP (~3.1 fold) (p ≤ 0.001), and MMP-9 (~7.2 fold) (p ≤ 0.01), and a significantly 
decreased MMP-2 (~2.2 fold) (p ≤ 0.0001) mRNA levels (Fig. 8d).  
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Figure 7. Chemical inhibition of MT1-MMP activation does not change active MT1-
MMP levels, but does change MT1-MMP, MMP-2 and MMP-9 mRNA levels in 
MDA-MB-231 breast cancer cells.  
(a) Western blot analysis showing pro- and active MT1-MMP and phospho-ERK1/2 
protein levels following treatment of MDA-MB-231 breast cancer cells with MT1-MMP 
activation inhibitor Furin Inhibitor I (20 μM) or vehicle control (DMSO 0.1%). β-actin 
and total ERK1/2 respectively serve as loading controls. (b) Densitometry quantification 
of western blots for MT1-MMP protein isoforms in MDA-MB-231 cells treated with 20 
μM of Furin Inhibitor I, analyzed by two-way ANOVA followed by Tukey’s post hoc 
test; ns, p > 0.05 and for phospho-ERK1/2 protein exhibiting significantly decreased 
phospho-ERK1/2, Student’s t-test; *, p ≤ 0.05. (c) qPCR analysis of MT1-MMP, MMP-2, 
and MMP-9 mRNA in MDA-MB-231 cells treated with either DMSO (0.1%) or Furin 
inhibitor I (20 μM). Fold change was quantified using the ΔΔCT method and shown as 
mean ± SEM. MDA-MB-231 cells treated with Furin Inhibitor I show significantly 
increased MMP-2 mRNA levels and significantly decreased MMP-9 mRNA levels, 
Student’s t-test; *, p ≤ 0.05. The inverse change in gelatinase mRNA levels upon treated 
with Furin inhibitor I is a conserved relationship between MCF-7 MT1-MMP C2 and 
MDA-MB-231 breast cancer cell lines. 
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Figure 8. Overexpression of α1-PDX in MDA-MB-231 breast cancer cells alters 
MT1-MMP activation causing changes in MT1-MMP protein forms, ERK1/2 
phosphorylation, and MMP expression. 
(a) qPCR analysis of alpha1-Antitrypsin Portland (α1-PDX) mRNA a protein which 
binds and inhibits the protein convertase activity of furin confirms its overexpression, in 
generated MDA-MB-231 cells stably expressing alpha1-Antitrypsin Portland (231-PDX 
cells). Fold change was quantified using the ΔΔCT method and shown as mean ± SEM, 
Student’s T-test; ***, p ≤ 0.001. (b) Western blot analysis showed pro- and active MT1-
MMP protein and ERK1/2 phosphorylation in MDA-MB-231 breast cancer cells and 
231-PDX cells. β-actin and total ERK1/2 served as loading controls. (c) Densitometry 
quantification of MT1-MMP pro- and active protein forms in MDA-MB-231 and 231-
PDX cells, exhibited significantly more pro- MT1-MMP in 231-PDX cells, (Two-way 
ANOVA followed by Sidak’s post hoc test; ***, p ≤ 0.001, **, p ≤ 0.01) and phospho-
ERK1/2 protein levels, showing significantly increased ERK1/2 phosphorylation 
(Student’s t-test; *, p ≤ 0.01). (c) qPCR analysis MT1-MMP, MMP-2, and MMP-9 
mRNA in MDA-MB-231 and 231-PDX cells. Fold change was quantified using the 
ΔΔCT method and shown as mean ± SEM. 231-PDX cells exhibited significantly 
decreased MMP-2 mRNA levels and significantly increased MMP-9 mRNA according to 
Student’s T-test ; ****, p ≤ 0.0001, ***, p ≤ 0.001.  
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3.4 Low levels of pro-MT1-MMP and high levels of active 
MT1-MMP in stable MT1-MMP overexpression MDA-
MB-231 cell lines resulted in increased MMP-9 mRNA 
levels 
Three MDA-MB-231 cell lines stably overexpressing MT1-MMP were generated to 
determine if the levels of pro- and active MT1-MMP protein influenced the transcription 
of other MMPs. Similar to the MCF-7 cell lines described previously, these cell lines 
were MDA-MB-231 MT1-MMP C1 which had high levels of both pro- and active MT1-
MMP, MDA-MB-231 MT1-MMP C2 which had low pro and predominantly active levels 
of MT1-MMP, and MDA-MB-231 MT1-MMP C3 which had low pro and slightly more 
active MT1-MMP protein compared to MDA-MB-231 parental cells as shown by 
western blot (Fig 9a). For simplicity, these cell lines will be referred to as MDA-MB-231 
C1, C2 and C3, respectively. Both MDA-MB-231 C2 and C3 cell lines exhibited high 
MMP-9 mRNA levels coupled with lower MMP-2 mRNA levels, while MDA-MB-231 
C1 cells displayed the opposite of low MMP-9 mRNA levels in conjunction with high 
MMP-2 mRNA levels. MDA-MB-231 C1 cells had ~9 fold significantly (p ≤ 0.0001) 
increased MMP-2 mRNA levels and ~13-fold significantly (p ≤ 0.0001) decreased MMP-
9 mRNA levels (Fig. 9b), which were confirmed at the protein level using gelatin 
zymography analysis (Fig. 9c).  When the MDA-MB-231 MT1-MMP overexpression 
stable cell lines were treated for 12 hours in serum-free medium conditioned with pro-
MMP-2, gelatin zymography analysis showed that all three cell lines have the ability of 
activate pro-MMP-2 (Fig. 9c), however MDA-MB-231 C1 cells activated the most pro-
MMP-2. Genetically altering MDA-MB-231 cells to overexpress different levels of MT1-
MMP, subsequently changed the levels of pro- and active MT1-MMP protein forms 
present in each cell line. This in turn influenced MMP-2 and MMP-9 mRNA levels in 
consistently opposite directions.  
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Figure 9. MT1-MMP over-expression in MDA-MB-231 breast cancer cells alters 
pro- and active MT1-MMP protein forms and subsequently results in distinct 
inverse relationships between MMP-2 and MMP-9 gene expression. 
(a) Western blot analysis showing pro- and active MT1-MMP protein in MDA-MB-231 
breast cancer cells and three clonally selected MDA-MB-231 cell lines that stably express 
different levels of MT1-MMP, which result in altered levels of pro- and active MT1-
MMP protein forms. β-actin was used as a loading control. (b) qPCR analysis of MMP-2 
and MMP-9 mRNA from isolated from MDA-MB-231 cells and three MDA-MB-231 
MT1-MMP over expression stable cell lines. Fold change was quantified using the ΔΔCT 
method and shown as mean ± SEM. One-way ANOVA followed by Tukey’s post-hoc 
test; ****, p ≤ 0.0001, **, p ≤ 0.01. MDA-MB-231 C1 cells displayed the inverse 
expression relationship between MMP-2 and MMP-9 a significant increase and a 
significant decrease in mRNA levels respectively. (c) Gelatin zymography analysis of 
MDA-MB-231 parental and MDA-MB-231 MT1-MMP over expression stable cell 
protein extracts incubated for 12 hours with serum-free medium (control) or serum-free 
medium supplemented with conditioned medium containing pro-MMP-2. Red asterisks 
highlights low levels of pro-MMP-9 protein present in the MDA-MB-231 MT1-MMP C1 
stable cell line corroborating the low MMP-9 mRNA levels observed by qPCR. 
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3.5 MEK1/2 inhibitor decreased NF-κB transcription while 
AP-1 transcription was unaffected in MCF-7 MT1-MMP 
and MDA-MB-231 breast cancer cells 
To further investigate possible mechanisms for the observed changes in MMP-2 and 
MMP-9 mRNA levels and alterations to cell invasive potential, a luciferase gene reporter 
assay was conducted to assess the transcriptional activity of AP-1 and NF-kB 
transcription factors. Plasmids encoding luciferase under the regulation of either AP-1 or 
NF-kB promoters were transiently transfected into MCF-7, MCF-7 C2, MDA-MB-231, 
and 231-PDX, which were incubated for 24 hours, then subjected to DMSO (0.1%), 
U0126 (10 μM), or BB-94 (10 μM) treatment for 12 hours.  
MCF-7 cells displayed significantly more AP-1 (p ≤ 0.001) and less NF-κB (p ≤ 0.0001) 
transcriptional activity compared to MCF-7 C2 cells, which had less AP-1 and more NF-
κB (Fig. 10a and b). Neither MCF-7 nor MCF-7 C2 cells displayed any significant 
change in AP-1 transcriptional activity following inhibitor treatment. However, in MCF-7 
C2 cells, U0126 evoked a significant (p ≤ 0.01) ~1.5 fold decrease in NF-κB 
transcriptional activity, while BB-94 treatment had no statistical effect (Fig. 10b). Both 
untreated MDA-MB-231 and 231-PDX cells showed a similar pattern of AP-1 and NF-
κB transcriptional activity to MCF-7 C2 cells, that of low AP-1 and high NF-κB 
transcriptional activity. Moreover, treatment of MDA-MB-231 cells with U0126 caused a 
significant (p ≤ 0.05) ~1.95 fold decrease in NF-κB transcriptional activity, a decrease 
also observed in the 231-PDX cell line (Fig. 10c and d). These results suggest that the 
levels of phosphorylated ERK1/2 present within each breast cancer cell line heavily 
influenced NF-κB transcriptional activity and that this is conserved among breast cancer 
cell lines. 
3.6 Only MDA-MB-231 cells treated with MERK1/2 inhibitor 
exhibited both reduced migratory and invasive potential 
The migratory potential of MDA-MB-231 cells was examined through treatment with 
DMSO (0.1%), U0126 (10 μM), BB-94 (10 μM), or Furin Inhibitor I (20 μM) during  
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Figure 10. Inhibition of ERK1/2 phosphorylation affects transcription of NF-κB 
more strongly than inhibition of MT1-MMP catalytic site activity in breast cancer 
cells.  
(a, b) MCF-7 breast cancer cells and MCF-7 MT1-MMP C2 cells were seeded at a 
density of 3.0x10
4
/mL and transfected with mammalian 3xAP-1 or 3xNF-κB luciferase 
reporter plasmids. After 24 hours of transfection, cells were treated with DMSO (0.1%), 
U0126 (10 μM), or BB-94 (10 μM) for 12 hours. Bioluminescent signal resulted from the 
oxidation of D-Luciferin. Luciferase activities in triplicate samples were measured. 
Values represent mean ± SEM from three independent transfection experiments. MCF-7 
cells contained more AP-1 and less NF-κB transcriptional activity compared to MCF-7 
C2 cells, One-way ANOVA followed by Tukey’s post hoc test; ****, p ≤ 0.0001,***, p ≤ 
0.001, **, p ≤ 0.01. (c, d) MDA-MB-231 breast cancer cells treated with either DMSO 
(0.1%), U0126 (10 μM), or BB-94 (10 μM), and MDA-MB-231 cells stably expressing 
alpha1-Antitrypsin Portland (α1-PDX), 231-PDX, were seeded at a density of 
3.0x10
4
/mL and transfected with mammalian 3xAP-1 or 3xNF-kB luciferase reporter 
plasmids. After 24 hours of transfection, cells were treated with DMSO (0.1%), U0126 
(10 μM), or BB-94 (10 μM) for 12 hours. Bioluminescent signal resulted from the 
oxidation of D-Luciferin. Luciferase activities in triplicate samples were measured. 
Values represent mean ± SEM from three independent transfection experiments. MDA-
MB-231 cells contained less AP-1 and more NF-κB transcriptional activity, whereby 
treatment of MDA-MB-231 cells caused a significant decrease in NF-κB transcriptional 
activity, One-way ANOVA followed by Tukey’s post hoc test; *, p ≤ 0.05. 
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a scratch wound closure assay over a 24-hour period, where images were taken at 2, 6, 
12, and 24 hours (Fig. 11a). Only MDA-MB-231 cells treated with U0126 were 
significantly (p ≤ 0.01) less efficient at wound closure, showing ~12% decrease and were 
therefore less migratory, compared to DMSO (0.1%) treated cells at 12 hours post wound 
generation (Fig. 11b). The impact of MEK1/2 inhibition, MMP site inhibition, and 
alteration of MT1-MMP activation, on migratory and invasive potential in MDA-MB-
231 cells were also investigated using transwell assays. MDA-MB-231 cells were treated 
with DMSO (0.1%), U0126 (10 μM), or BB-94 (10 μM), and 231-PDX cells, where 
migration was observed through uncoated transwell insert, or invasion through a 
Matrigel-coated transwell insert, for 24 and 48 hours respectively. MDA-MB-231 cells 
treated with the MEK1/2 inhibitor U0126 were significantly (p ≤ 0.01) by 25% less 
efficient at migration through the transwell pores, while the pan-MMP catalytic site 
inhibitor BB-94 did not affect the migratory ability of these cells (p > 0.05). It is not 
surprising that inhibition of MMP catalytic site activity did not affect MDA-MB-231 
migratory potential, as there was no physical barrier present to be degraded.  231-PDX 
cells were significantly (p ≤ 0.01) 19% less migratory compared to MDA-MB-231 
parental cells. (Fig. 11c). 
When Matrigel was present and invasion required, MDA-MB-231 cells treated with 
U0126 were significantly (p ≤ 0.0001) 90% less efficient at invading through the barrier, 
as were BB-94 treated cells that were significantly (p ≤ 0.0001) 62% less efficient 
compared to DMSO (0.1%) treated MDA-MB-231 cells. 231-PDX cells were also 
significantly (p ≤ 0.5) 10% less invasive compared to MDA-MB-231 parental cells. 
These results demonstrated the overall importance of phospho-ERK1/2 signalling in 
influencing cell movements, as impeding this signalling pathway affected both migratory 
and invasive potential of MDA-MB-231 cells, a well-classified invasive breast cancer 
cell type (Fig. 11c). 
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Figure 11. Inhibition of ERK1/2 phosphorylation is more influential on cell 
migration and invasion than inhibition of MMP enzymatic activity or MT1-MMP 
activation.  
(a) MDA-MB-231 breast cancer cells were seeded at a density of 2.5x10
5
/mL, treated 
with either DMSO (0.1%), U0126 (10 μM), BB-94 (10 μM), or Furin Inhibitor I (20 μM), 
and allowed to form a monolayer for 24 hours. A scratch was made in the monolayer and 
the closure of this scratch was monitored at time points of 2, 6, 12, and 24 hours after the 
initial scratch. White dotted lines indicate the initial scratch size; red dotted lines indicate 
the scratch size at the respective times point. (b) Scratch closure was quantified by 
dividing the width of the scratch at the respective day by the initial scratch size and then 
expressing it as mean percentage ± SEM, as analyzed by one-way ANOVA followed by 
Tukey’s post hoc test; **, p ≤ 0.01, ns, p > 0.05. Scale bars = 100 μm. U0126 treatment 
was successful at decreasing migration up until 12 hours post wound generation. (c) 
Twenty thousand MDA-MB-231 cells treated with either DMSO (0.1%), U0126 (10 
μM), or BB-94 (10 μM), or 231-PDX cells, were seeded onto a transwell insert 
(migration), or an insert coated with 20% Matrigel (invasion), and incubated for 24 
(migration) and 48 hours (invasion) respectively. Number of migrated/invaded cells were 
normalized to DMSO (0.1%) treated MDA-MB-231 cells and expressed as a mean 
percentage ± SEM. One-way ANOVA followed by Tukey’s post hoc test; ****, p ≤ 
0.0001, **, p ≤ 0.01, *, p ≤ 0.05. Both migration and invasion of MDA-MB-231 cells 
was significantly decreased following U0126 treatment. BB-94 treatment however, only 
affected invasion resulting in a significant decrease in invasive potential of MDA-MB-
231 breast cancer cells. 231-PDX cells also less migratory and less invasive compared to 
MDA-MB-231 cells.  
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3.7 MDA-MB-231 cells with decreased ERK1/2 
phosphorylation, inhibited MMP catalytic activity, or 
altered MT1-MMP activation all exhibited morphological 
changes in 3D cell culture 
In order to determine the effects of the inhibitors used on cell morphology, MDA-MB-
231 and 231-PDX cells were embedded in 50% Matrigel and treated with DMSO (0.1%), 
U0126 (10 μM), or BB-94 (10 μM). By Day 5, morphological differences among the 
treatments were apparent (Fig 12a). MDA-MB-231 cells treated with U0126 (10 μM) and 
BB-94 (10 μM) were significantly (p ≤ 0.0001) less protrusive (~ 2- 3 protrusions per  
colony) than MDA-MB-231 parental cells (~9 per colony) or 231-PDX cells (~6 per 
colony). Alternatively, MDA-MB-231 cells treated with U0126 and BB-94, and 231-  
PDX cells all had significantly (p ≤ 0.01) more disseminations per colony compared to 
MDA-MB-231 cells treated with DMSO (Fig. 12b). These results indicated that treatment 
altering ERK1/2 phosphorylation, MT1-MMP activity, or MT1-MMP activation caused 
changes within these cells to divide and move rather than remain stationary and invade. 
Control MDA-MB-231 cells treated with DMSO displayed a meshwork phenotype of 
cells resulting from a combination of round clumped and elongated cells. Inhibition of 
ERK1/2 phosphorylation achieved by U0126 treatment abolished the ability of MDA-
MB-231 cells to from elongated processes and resulted in small round single cells with 
very concentrated F-actin. Inhibition of MMP catalytic activity through treatment with 
BB-94 resulted in large distinct aggregations of round cells, however some BB-94 treated 
MDA-MB-231 cells were still able to elongate in a manner similar to the morphology of 
control cells. Lastly, 231-PDX cells exhibited large round clumps of cells that lacked 
long elongated cell morphology (Fig 12c). The morphological changes observed in each 
treatment and cell line were supported by quantitative analysis of protrusions and 
disseminations per cell colony. 
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Figure 12. Interfering with MT1-MMP activation, MT1-MMP catalytic activity, and 
MAPK signalling affects 3D morphology of MDA-MB-231 breast cancer cells.  
(a) MDA-MB-231 breast cancer cells treated with DMSO (0.1%), U0126 (10 μM), or 
BB-94 (10 μM), and MDA-MB-231 cells stably expressing alpha1-Antitrypsin Portland, 
231-PDX, were embedded in 50% Matrigel and incubated in medium containing 10% 
FBS with the respective inhibitor treatment. Images were taken every day for 5 days 
using DIC microscopy at 10x (50 μm z-stacks, 2 μm slices). Shown is a representative 
focal panel field of view of each cell line with respective treatment at day 1, 3, and 5. 
Scale bars = 100 μm. (b) Five z-stacks per cell line/treatment were acquired and 
disseminations and protrusions were blindly counted and expressed as a mean normalized 
to the colony number per z-stack ± SEM. MDA-MB-231 breast cancer cells treated with 
DMSO (0.1%) exhibited the highest number of protrusions per colony but lowest number 
of disseminations per colony, while MDA-MB-231 cells treated with U0126 (10 μM) 
exhibited the lowest number of protrusions per colony, but the highest number of 
disseminations per colony, as analyzed two-way ANOVA followed by Tukey’s post hoc 
test; ****, p ≤ 0.0001, **, p ≤ 0.01. (c) MDA-MB-231 cells treated with DMSO (0.1%), 
U0126 (10 μM), or BB-94 (10 μM), and MDA-MB-231 cells stably expressing alpha1-
Antitrypsin Portland, 231-PDX, were embedded in 50% Matrigel, incubated in medium 
containing 10% FBS with the respective inhibitor treatment for 5 days and processed for 
immunocytochemistry to examine nuclei and F-actin distribution. Samples were imaged 
using confocal microscopy at 20x and 60x and are displayed as a 3D volume overlay 
showing DAPI (blue) and Alexa Fluor 633 phalloidin (red) channels, where all treatments 
are morphologically different from one another. Scale bars = 100 μm. All experiments 
were repeated in triplicate with comparable results. 
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3.8 Changes in MT1-MMP activation, ERK1/2 
phosphorylation, and MMP-2 and MMP-9 mRNA levels 
in vitro contributed to in vivo tumour growth 
To assess the role of level of MT1-MMP activation, MMP activity, and ERK1/2 
phosphorylation in tumourigenicity, artificial Matrigel tumours composed of ZsMDA-
MB-231 and Zs231-PDX cells were injected into a wound in the CAM vasculature of a 
nine-day-old chicken embryo and incubated for eight days. ZsMDA-MB-231 Matrigel 
tumours were subjected to DMSO (0.1%), U0126 (10 μM), or BB-94 (10 μM) every 48 
hours. Following incubation, vascularization of the tumour site was observed.  ZsMDA-
MB-231 Matrigel tumours treated with DMSO (0.1%) had the highest incidences of 
vascularization (19/21) and complete wound closure (13/16 closed) at the injection site. 
Conversely, ZsMDA-MB-231 tumours treated with U-0126 had the least incidences of 
vascularization (3/14) and incomplete wound closure (1/12 closed), while BB-94 treated 
ZsMDA-MB-231 tumours displayed reduced incidences of vascularization (5/12) and  
decreased wound closure (2/10 closed). Zs231-PDX tumours exhibited intermediate 
vascularization (9/13) and variable wound closure (3/8 closed) (Figure. 13a-c).  
Excision and cross sectioning of ZsMDA-MB-231 control Matrigel tumours revealed 
vascularization not only on the surface of the tumor, but also throughout (Figure. 13d). 
Internal vascularization of ZsMDA-MB-231 control tumours indicates the possibility that 
other Matrigel tumors with surface vascularization contain additional vasculature running 
throughout the inside of the tumors (Data to be published in Cepeda et al., 2016). 
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Figure 13. MDA-MB-231 breast cancer cells treated with U0126 showed fewer 
incidences of vascularization and wound closure within avian CAM.  
ZsGreen-tagged MDA-MB-231 (ZsMDA-MB-231 and ZsGreen-tagged 231-PDX 
(Zs231-PDX) cell lines were combined with Matrigel and injected into a wound made in 
the vasculature of the CAM of a nine-day-old chicken embryo. Embryos were incubated 
for eight days, the introduced cells were treated with either DMSO (0.1%), U0126 (10 
μM), or BB-94 (10 μM), every 48 hours directly onto the tumour injection site. Nine days 
post wound generation; bright field and fluorescence stereomicroscopy were used to 
examine the tumour site, where vascularization of the tumour was assessed by identifying 
novel capillaries around the tumours growing within the CAM. Wound closure was 
assessed based on growth and closure of scar tissue via the resultant lack of tumour 
present above the CAM and regression of originally wounded vessels. (a) Representative 
bright field and fluorescence microscopy images of complete and partial submersion of 
tumours beneath the CAM at day nine post wound generation. Complete submersion of 
tumours beneath CAM with ZsMDA-MB-231 (top panel) and Zs231-PDX cells (bottom 
panel). Partial submersion of tumour treated with U0126 (10 μM) and BB-94 (10 μM). 
Blue arrows indicate submerged tumours, yellow arrows represent tumours that remained 
above the CAM. Scale bars = 2 mm. (b) Enlarged bright field and fluorescence 
stereomicroscopy images of areas denoted by red boxed outline in (a) of ZsMDA-MB-
231 cells treated with DMSO (0.1%) and U0126 (10 μM) to show vascularization and 
wound closure. Left panels (top and bottom), show high levels of vascularization 
surrounding DMSO (0.1%) treated tumours (black arrows), and the most incidence of 
complete wound closure (black outline, red arrow). Vascularization in ZsGreen cells is 
visualized as darkened areas of contrast against green fluorescence (white outline, black 
arrow), right panels (top and bottom). Inhibitor (U0126, 10μM) treated tumours displayed 
a vascularization that looped away from the tumour (black arrow heads) accompanied by 
incomplete wound closure delineated by scabbed borders (black outline, red arrows). 
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Scale bar = 1mm. (c) Multiple chicken embryos (N ≥ 12) were wounded, injected, and 
had tumour sites assessed for vascularization and completeness of wound closure. 
ZsMDA-MB-231 cells treated with DMSO (0.1%) had the highest number of incidences 
of vascularization and complete wound closure. ZsMDA-MB-231 Matrigel tumours 
treated with U0126 (10 μM) showed the least incidences of tumour vascularization and 
incomplete wound closure, while BB-94 (10 μM) treated tumours exhibited intermediate 
incidences of tumour vascularization and incomplete wound closure. Zs231-PDX 
Matrigel tumours displayed intermediate incidences of tumour vascularization and 
variable wound closure. A chi-squared test of independence was performed to examine 
the relationship between cell line / treatment and vascularization.  The relationship 
between these variables was significant X
2 
(4, N= 59) = 19.76; ***,p <0.001. A chi-
squared test of independence was performed to examine the relationship between cell line 
/ treatment and wound closure.  The relationship between these variables was significant 
X
2 
(4, N= 46) = 17.83; ***,p <0.001. (d) A tumour from MDA-MB 231 cells expressing 
ZsGreen was excised from a chicken embryo 8 days post-implantation and imaged using 
brightfield and fluorescence microscopy. Vessels within the tumour (white arrows) can 
be seen by the presence of blood (dark colour) and absence of fluorescent signal 
(ZsGreen), which indicate that these vessels originate from the chicken embryo.  Excision 
of the tumour revealed vascularization present on the surface of the tumour, and cutting 
the tumour in cross section showed vascularization throughout the center (white arrows). 
The image of the upper half of the tumour is maintained in original position, while the 
lower half of the sectioned tumour is rotated 90° to reveal internal vessels.  Scale bars = 2 
mm. (e) Schematic illustration representing the relative positions of the tumours within 
the cam CAM, and vasculature. Shown are cross-sections perpendicular to the images 
shown in (a). i) Un-invaded, un-vascularized tumours remain sitting on top of the CAM, 
representative of incidences of tumour rejection. ii) Vascularized tumours that retain an 
open wound were seen in ZsMDA-MB-231 cells treated with inhibitors and Zs231-PDX 
cells. iii) Vascularized tumours with complete CAM wound closure and vascularization, 
occurred with ZsMDA-MB-231 DMSO (0.1%) and Zs231-PDX tumours.  
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Chapter 4  
4 Discussion 
This work aimed to examine the effects of MT1-MMP proteolytic and non-proteolytic 
functions on the invasive ability of cells, by manipulating MT1-MMP activation 
(chemically and genetically), catalytic activity (chemically), and ERK1/2 
phosphorylation (chemically). This study used MCF-7 breast cancer cells, which are 
deficient in MT1-MMP and phospho-ERK1/2, as well as other cell lines, which have 
increased MT1-MMP levels (MCF-7 MT1-MMP C2), high levels of active MT1-MMP 
and phospho-ERK1/2 (MDA-MB-231 cells), and cells that have altered levels of active 
MT1-MMP and phospho-ERK 1/2 (231 PDX cells). These cells all were subjected to 
inhibitors targeting ERK1/2 phosphorylation (U-0126), MMP catalytic activity (BB-94), 
and furin convertase activity (Furin inhibitor I). I hypothesized that inhibiting ERK1/2 
phosphorylation, MMP catalytic activity, or furin convertase activity, would alter the 
expression of key ECM remodeling proteins, the gelatinases (MMP-2 and MMP-9) and 
subsequently alter breast cancer cell invasion. My results indicate that inhibiting MT1-
MMP activation or activity, or ERK1/2 phosphorylation, results in an inverse 
expressional relationship between MMP-2 and MMP-9 and reduced cell invasion. 
Moreover, a possible pathway influencing breast cancer cell invasion can be proposed: 
Active MT1-MMP is required to initiate the MAPK signalling pathway, resulting in 
ERK1/2 phosphorylation, and subsequent transcriptional activity of NF-κB to influence 
MMP-9 transcription. This model will be discussed below by examining the overall 
effects (changes in transcription, protein levels, and cell motility) of inhibiting ERK1/2 
phosphorylation, MMP catalytic activity, or MT1-MMP activation in individual sections.  
4.1 Inhibiting ERK1/2 phosphorylation inversely effects 
gelatinase expression, reduces total MT1-MMP active 
protein levels, and decreases migratory and invasive 
potential of breast cancer cells 
Proper phospho-ERK1/2 signalling is essential in many cellular processes including 
migration, proliferation, and apoptosis (Fujioka et al., 2006). As discussed below, 
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treatment of MCF-7, MCF-7 C2, and MDA-MB-231 cells with MEK1/2 kinase inhibitor 
(U-0126) decreases phospho-ERK1/2 and alters MT1-MMP, MMP-2, and MMP-9 mRNA 
levels (Fig. 2 and 3). Total MT1-MMP protein is decreased (Fig. 4a and b), as well as 
migration and invasion in 2D and 3D space are reduced (Fig. 11, 12, 13).  
4.1.1 Decreasing ERK1/2 phosphorylation increased 
MMP-2 mRNA levels, but decreased MMP-9 mRNA 
levels in MCF-7 MT1-MMP C2 and MDA-MB-231 
breast cancer cells 
The binding of TIMP-2 to the hemopexin domain of MT1-MMP initiates the MAPK 
pathway by an uncharacterized mechanism to result in the phosphorylation and 
successive activation of ERK1/2 — this activation being a non-proteolytic function of 
MT1-MMP. Sequentially, phospho-ERK1/2 is translocated to the nucleus of the cell to 
influence transcription factors, including AP-1, which is known to regulate the 
transcription of a broad number of MMPs, and NF-κB, which regulates only specific 
MMPs, namely MT1-MMP and MMP-9 (Overall, and López-Otín 2002). 
Inhibiting ERK1/2 phosphorylation in both MCF-7 C2 and MDA-MB-231 cells resulted 
in increased MMP-2 and decreased MMP-9 mRNA levels (Fig. 2b and 3c), indicating 
that the mechanism between phospho-ERK1/2 and gelatinase expression is conserved 
between breast cancer cell lines. Additionally, as decreasing phospho-ERK1/2 decreased 
MMP-9 mRNA levels, but increased MMP-2 mRNA levels, it can be surmised that 
phospho-ERK1/2 acts directly upon transcription factors to positively influence MMP-9 
expression, and negatively affect MMP-2 expression. Both MMP-2 and MMP-9 are 
considered potent ECM remodelers as they share the target substrate collagen IV, an 
abundant component of basement membranes. Active degradation of basement 
membrane substrate is needed in many critical developmental events such as epithelial to 
mesenchymal transitions, and is also needed for cancer cell invasion and for metastasis to 
occur (Hotary et al., 2006). 
 
The MMP transcriptional regulatory mechanisms are complex. Most MMPs are not 
expressed in adult cells under quiescent conditions, but their transcription can be induced 
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in tumour or stromal cells by various signals, such as cytokines, growth factors and 
oncogene products. Additionally, the signal-transduction pathways that mediate the 
activity of MMP transcriptional activators are also diverse. NF-κB is known to interact 
with phospho-ERK1/2 and is well known for its importance in regulation of MMP-9 
expression (Overall, and López-Otín 2002). Here, inhibition of phospho-ERK1/2 in 
MCF-7 C2 and MDA-MB-231 cells resulted in decreased NF-κB transcriptional activity, 
indicating further support for a mechanism of phospho-ERK1/2 regulation of MMP-9 
(Fig. 10b and d). A similar study performed by Lee et al., (2013) in bladder cancer cells, 
also suggests a relationship among phospho-ERK1/2, NF-κB, and MMP-9 expression. 
Lee et al., (2013) demonstrated in bladder cancer cells that upon chemical inhibition of 
phospho-ERK1/2, NF-κB transcriptional activity and MMP-9 expression was decreased. 
To confirm regulation of MMP-9, NF-κB transcriptional activity was also chemically 
inhibited and resulted in decreased MMP-9 expression in bladder cancer cells. To further 
support the relationship among phospho-ERK1/2, NF-κB, and MMP-9 mRNA levels as 
presented here (Fig. 2, 3 and 10), assays should be performed in MCF-7, MCF-7 C2, and 
MDA-MB-231 cells with an NF-κB inhibitor to observe changes that occur in ERK1/2 
phosphorylation, as well as MMP-2 and MMP-9 mRNA levels. When these cells are 
treated with the NF-κB inhibitor, it is proposed that ERK1/2 phosphorylation will remain 
basal, MMP-9 mRNA levels will be decreased, and MMP-2 mRNA levels will be 
unaffected as the promoter region of MMP-2 does not contain a NF-κB binding domain 
(Overall, and López-Otín 2002). However, when cells are treated with inhibitors for both 
ERK1/2 phosphorylation and NF-κB, a decrease in phospho-ERK1/2 and MMP-9 
expression are predicted, whereas MMP-2 mRNA levels remains increased. The 
regulation of MMP-2 expression through phospho-ERK1/2 is more complex than that just 
described for MMP-9. AP-2 has been shown in various other cell types to be critically 
responsible for MMP-2 expression (Fig. 1) (Overall and López-Otín, 2002). The 
MAPK/ERK pathway is known to interact with the PI3K/AKT pathway, as Ras also 
activates PI3K resulting in the activation of AKT, with AP-2 a downstream target of 
AKT. To investigate this proposed interaction, AKT phosphorylation and AP-2 
transcriptional activity should be targeted to observe changes in MMP-2 expression 
(Moulick et al., 2013). 
68 
 
Inhibition of ERK1/2 phosphorylation additionally decreased MT1-MMP mRNA levels 
in MDA-MB-231 cells (Fig. 3c) and decreased total MT1-MMP protein in MCF-7 C2 
cells (Fig. 4a), indicating that the mechanism regulating phospho-ERK1/2 and MT1-
MMP is conserved between breast cancer cell lines. Transcriptional regulation of MT1-
MMP may occur in similar fashion to that of MMP-9 —through phospho-ERK1/2’s 
influence on NF-κB transcriptional activity, as the MT1-MMP promoter also contains an 
NF-κB binding domain (Overall and López-Otín 2002). Interestingly, only MCF-7 C2 
cells exhibited decreased total MT1-MMP, specifically less active MT1-MMP protein, 
despite both cell lines having decreased MT1-MMP RNA levels. MDA-MB-231 MT1-
MMP protein levels remained unaffected, indicating differential post transcriptional or 
post translational regulation of MT1-MMP transcript in this more invasive breast cancer 
cell line.  
 
Collectively, decreased MMP-9 and MT1-MMP mRNA levels following inhibition of 
ERK1/2 phosphorylation observed in this study is consistent with other studies. This 
relationship is well documented and occurs in many different cell lines such as 
rhabdomyosarcoma, fibrosarcoma, bladder carcinoma, colon adenocarcinoma, and 
prostate carcinoma (Tanimura et al., 2003). However, my observation of increased MMP-
2 mRNA levels following decreased phospho-ERK1/2, is novel as previously MMP-2 
and -9 mRNA levels are always altered in the same direction, while in this study, levels 
are always inverse. 
s 
 4.1.2 Decreased migratory and invasive potential is 
observed with decreased phospho-ERK1/2 in vitro, ex 
vivo, and in vivo in MDA-MB-231 breast cancer cells 
Phospho-ERK1/2 influences the migratory and invasive potential of cells through 
activation of a multitude of genes whose products control cytoskeletal arrangements, 
presence or absence of cell surface receptors, ECM degradation, and the release of 
cytokines and growth factors. Consequently, inhibition of ERK1/2 phosphorylation in 
invasive MDA-MB-231 cells resulted in decreased migration (Fig. 11) and invasion in 
diverse assays investigating cell motility (Fig. 11c, 12, and 13). This study further 
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supports the necessity of proper phospho-ERK1/2 signalling in order to achieve cell 
migration and invasion (Meloche, and Pouysségur, 2007). 
Invasive capabilities were examined using a transwell invasion assay and 3D cell culture, 
both of which showed decreased invasive potential following treatment with the MEK1/2 
kinase inhibitor, U0126. Acquisition of an invasive phenotype requires modulation of 
cell-ECM interactions through cytoskeletal organization, proteolysis of the extracellular 
matrix, and migration (Friedl and Wolf, 2003). 
 
Upon inhibition of ERK1/2 phosphorylation in 3D cell culture, the morphology of MDA-
MB-231 breast cancer cells changes to become round, with a minimally protrusive 
phenotype, as fluorescence microscopy revealed a condensed and aggregated F-actin 
cytoskeletal network, contrasting that which forms in untreated cells (Fig. 12c). Previous 
studies have found that the filamentous F-actin regulatory protein, cortactin, plays an 
important role in tumour cell movement and invasion through organization of plasma 
membrane protrusions. Cortactin is positively regulated through phosphorylation by 
phospho-ERK1/2, to promote APR2/3-mediated actin networks (Kelley et al., 2011). The 
reduction of protrusions and associated condensed actin phenotype observed in 3D cell 
culture following treatment with U0126 could be attributed to deficiency in cytoskeletal 
organization, such as cortactin stabilization. 
For reduced invasion, in addition to deficiencies in cytoskeletal arrangement, degradation 
of ECM substrates is also thought to be compromised. Breast cancer cells in which 
ERK1/2 phosphorylation was inhibited also exhibited changes in mRNA and altered 
protein levels of MT1-MMP, MMP-2, and MMP-9. Specifically, cells with decreased 
phospho-ERK1/2 consequently have decreased active MT1-MMP (Fig. 4b and c) and 
pro-MMP-9 protein, but elevated levels of pro-MMP-2 protein (Fig. 3a). With a resultant 
lack of active MT1-MMP present on the cell surface, MT1-MMP-medicated pro-MMP-2 
activation would also be reduced consequently reducing the activation of pro-MMP-9. 
Therefore cells with decreased phospho-ERK1/2 also have minimal ability to degrade 
ECM constituents as evidenced by reduced invasive potential in the Matrigel coated 
transwell invasion assay (Fig. 11c). 
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MT1-MMP is essential for forming filipodia and lamellipodia in migration and 
invadapodia during invasion. The formation of invadapodia requires actin polymerization 
to form a membrane protrusion, followed by MT1-MMP shuttled to the distal end 
(Artym, 2006). While the basal machinery of invadapodia still functions in the absence of 
MT1-MMP, the resulting structures are non-functional and do not degrade ECM 
substrates (Buccione et al., 2009; Itoh et al., 2006). Thereby, the minimal protrusions that 
did form following U0126 treatment, in MDA-MB-231 cells, most likely lacked MT1-
MMP protein at the distal end, and also had reduced secretory vesicle transportation of 
gelatinase proteins to the cell surface that resulted from altered MT1-MMP expression 
and expected activation deficiency. 
 
To better understand the mechanisms involved in invasion, migration was investigated 
using scratch wound closure and transwell mediated assays, both of which demonstrated 
decreased migration when ERK1/2 phosphorylation was inhibited (Fig. 11). U0126 
treated MDA-MB-231 cells showed decreased scratch wound closure up until 12 hours 
post wound generation, after which distance migrated is equivalent to that of untreated 
cells at 24 hours. These changes could be a result of depleted inhibitor over time, or by 
increased cell number over time. During cell proliferation, rapid and persistent nuclear 
transfer of phosphorylated ERK1/2 during the entire G0 to G1 period of the cell cycle is 
crucial to ensure rapid cell growth and cell abundance (Mebratu and Tesfaigzi, 2009). As 
such, in the presence of U0126, proliferation of these cells is minimal, as they cannot 
transition out of G0, and thus if they do not enter the cell cycle, they can be more prone 
to cell migration. Therefore, comparable migratory ability between untreated and U0126 
treated MDA-MB-231 cells at 24 hours can be attributed to the decreased effect of 
inhibitor over time as apposed to cell proliferation. Consistent with the scratch assay, 
cells treated with U0126 and induced to migrate through a porous transwell barrier, also 
exhibited decreased migration. The transwell assay was performed over a 24-hour span, 
where only cells capable of cytoskeletal rearrangement pass through the barrier. 
Additional to cortactin stabilization, previous studies also indicate that phospho-ERK1/2 
activates cell motility machinery by enhancing myosin light-chain kinase (MLCK) 
activity leading to increased MLC phosphorylation and enhanced cell migration (Reddy 
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et al., 2003). Decreasing phospho-ERK1/2 would lead to the reduction of MLCK activity 
to result in decreased migration.  
Through targeting the MT1-MMP non-proteolytic function, ERK1/2 phosphorylation, 
both cytoskeletal organization and ECM proteolysis, which are necessary for invasion, 
have been considerably impaired. These observations are also of importance when 
assessing tumour vascularization and wound closure data observed in the CAM of 
chicken embryos. A wound was generated into the CAM vasculature whereby an 
artificial tumour consisting of Matrigel and MDA-MB-231 cells was injected. Treatment 
with U0126 resulted in the least number of incidences of tumor vascularization and 
incomplete wound closure compared to control MDA-MB-231 cells. As previously 
discussed, inhibition of phospho-ERK1/2 impairs migratory and invasive potential of 
cells to then prevent movement of cells. Additionally, growth factors critical to 
angiogenesis such as VEGF family members, can be sequestered within the ECM, and 
are cleaved by MMP-9 to stimulate proliferation and migration of endothelial cells 
(Bergers et al., 2000; Yu and Stamenkovic, 2000). Here MDA-MB-231 cells treated with 
U0126 expressed very little MMP-9 mRNA resulting in negligible levels of active MMP-
9; reduction of this gelatinase is one possible explanation for lack of tumour 
vascularization in the chick CAM model. Phospho-ERK1/2 signalling itself is also 
involved in numerous angiogenic processes such as endothelial cell division, influencing 
selective degradation of basement membrane structures, endothelial cell migration and 
the formation of tubular structures (Hoeben et al., 2004). Likewise, this can also affect 
vascularization of the tumour, as well as impairing growth of surrounding vessels. 
Moreover, the chicken tumor vascularization assay is a holistic in vivo assay, making 
exploring inhibitor effects solely on tumour cell invasion and vascularization difficult, as 
phospho-ERK1/2 inhibition is expected to be influencing cells not only within, but 
surrounding the tumour. Decreased vascularization and wound closure of U0126 treated 
MDA-MB-231 tumours in the chick CAM is most likely a combination resulting from 
inhibitory effects on both the cells within the tumour and nearby endothelial cells within 
the CAM. 
 
Exploring the effects of ERK1/2 phosphorylation through inhibition has revealed its 
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importance in diverse cellular processes involving MT1-MMP and gelatinase MMPs 
levels, cell migration and invasion, to ultimately modulate tumour vascularization and 
wound closure in an in vivo model. The usefulness of broad spectrum targeting of 
phospho-ERK1/2 through MEK1/2 kinase inhibition in breast cancer cells is mitigated by 
the many roles phospho-ERK1/2 plays in diverse cellular processes, including cancer 
progression. In order to further explore the cellular consequences of ERK1/2 inhibition in 
an MT1-MMP specific context, the hemopexin domain of MT1-MMP should be targeted 
to prevent the binding of TIMP-2 to decrease activation of the MAPK pathway and 
precisely investigate the downstream role of this ligand-receptor interaction.  
4.2 Inhibiting MMP catalytic activity increases total MT1-
MMP active protein levels, inversely effects gelatinase 
expression, and decreases invasive potential of breast 
cancer cells 
MMPs have been well documented to degrade all constituents of the ECM, influencing 
availability of growth factors, growth factor receptors, chemokines, and cell adhesion 
molecules, in order to elicit cell behaviours such as migration and invasion.  
As will be discussed below, treatment of MCF-7, MCF-7 C2, and MDA-MB-231 cells 
with a pan-MMP catalytic activity inhibitor batimastat (BB-94) subsequently alters MT1-
MMP, MMP-2 and MMP-9 mRNA levels, increases total MT1-MMP protein 
(predominately active MT1-MMP) (Fig. 4 and 5), as well as decrease invasive potential 
in 2D and 3D space (Fig. 11, 12, 13).  
4.2.1 Inhibition of MMP activity by BB-94 addition 
decreased MMP-2 mRNA levels, but increased MMP-9 
mRNA levels in MCF-7 MT1-MMP C2 and MDA-MB-
231 breast cancer cells 
Pan-inhibition of MMP catalytic activity in both MCF-7 C2 and MDA-MB-231 cells 
resulted in increased MT1-MMP expression, perhaps as a compensatory mechanism as 
active MT1-MMP protein levels were increased. Furthermore, BB-94 treatment of MCF-
7 C2 resulted in increased levels of ERK1/2 phosphorylation as shown by western blot 
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(Fig. 4a and b). Additionally, BB94 treated MCF-7 C2 and MDA-MB-231 cells exhibited 
decreased MMP-2, but increased MMP-9 mRNA levels (Fig. 4d and 5c), indicating that 
the mechanism of gelatinase expression, as it is proposed to be regulated by the activity 
state of MT1-MMP, is conserved between breast cancer cell lines. When the catalytic 
domain of MT1-MMP is inhibited, all proteolytic functions are decreased, including pro-
MMP-2 activation mediated by TIMP-2. Nonetheless, the hemopexin domain of MT1-
MMP is still available for TIMP-2 binding. In this situation increased phospho-ERK1/2 
levels seen following MMP catalytic site inhibition can be attributed to availability of the 
MT1-MMP hemopexin domain to still bind to TIMP-2 and initiate MAPK activation. 
Indeed, TIMP-2 mutants incapable of binding the MT1-MMP catalytic site are still able 
to induce the MAPK pathway (D'Alessio et al., 2008; Sounni et al., 2010). Thus, despite 
MMP catalytic inhibition, MAPK activation can still occur, whereby activity of phospho-
ERK1/2 could be influencing the increased expression of MT1-MMP in these two cell 
lines, perhaps as a compensatory mechanism for catalytic inhibition.  
Increased MT1-MMP mRNA is not a result of transcriptional activity of transcription 
factors AP-1 or NF-κB (Fig. 10), as their activity was not altered in the presence of MMP 
catalytic site inhibition. MT1-MMP transcriptional control is unique compared to other 
MMP family members due to differences in its promoter sequence. Lohi et al., (2000) 
identified a GC-rich region within the promoter region of MT1-MMP as the putative 
binding sequence for the Sp1 transcription factor in multiple cell lines (Sroka et al., 
2007). Phospho-ERK1/2 directly phosphorylates Sp1 to increase Sp1 transcriptional 
activity specifying this transcription factor as a possible target for increased MT1-MMP 
mRNA levels. Changes in Sp1 transcriptional activity should be investigated following 
BB-94 treatment in order to confirm involvement of this transcription factor. Ultimately 
the increase in MT1-MMP mRNA levels following catalytic site inhibition resulted in 
increased total MT1-MMP protein, with the greatest increase seen with active MT1-
MMP levels in MCF-7 C2 cells (Fig. 4b and c). More active MT1-MMP present on the 
cell surface, whether catalytically inhibited by BB-94 or not, would still have the ability 
to activate phospho-ERK1/2 signalling, and therefore influence MT1-MMP expression in 
a proposed positive loop. However, MDA-MB-231 MT1-MMP protein levels were not 
altered following treatment with BB-94, suggesting that the more invasive cells, unlike 
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the MCF-7 cells, regulate MT1-MMP differently both post transcriptionally and post 
translationally. 
In cells treated with BB-94, increased levels of active MT1-MMP resulted in increased 
ERK1/2 phosphorylation and increased mRNA levels of both MT1-MMP and MMP-9. 
These observations further support my hypothesis that a signalling pathway exists that 
co-regulates these proteins. However, in cells treated with BB-94, transcriptional activity 
of AP-1 and NF-κB remained unchanged by the application of the inhibitor (Fig. 10). As 
MMP-9 mRNA levels increased, changes in expression of these transcription factors is 
hypothesized to increase. Promotion of MMP-9 transcription is controlled by many other 
transcription factors such as KRE, TIE, and RCE (Fig. 1) (Overall and López-Otín, 
2002). Any of these regulating proteins can be turned on or repressed by phospho-
ERK1/2, and disrupt endogenous transcription factor stoichiometry to be influencing the 
increased expression of MMP-9 in cells treated with BB-94. Others have reported that the 
influence of phospho-ERK1/2 on MMP-2 expression is complex, where crosstalk 
between the PI3K/AKT pathway has been proposed (Moulick et al., 2013).  
In a proteolysis dependent pathway, a cell is proposed to be able to detect the cleavage 
ability of proteins on its cell surface. That being said, catalytically active MT1-MMP is 
necessary to activate pro-MMP-2. With a lack of ability by MT1-MMP to activate MMP-
2, a cell may have feedback mechanisms whereby the expression of MMP-2 is reduced, 
and MMP-9, which can be activated independently of MT1-MMP, would not be 
regulated by the same mechanism. 
4.2.2 Inhibition of MMP cleavage activity does not affect 
migration, but does decrease invasive potential of 
MDA-MB-231 breast cancer cells 
MT1-MMP localization is well characterized as it is found at the leading edge of cells 
during migration, and in membrane protrusions called invadapodia during invasion 
(Artym, 2006). MDA-MB-231 breast cancer cells are highly invasive yet upon treatment 
with the pan-MMP catalytic site inhibitor BB-94, invasion is drastically reduced as 
demonstrated by decreased invasion through a Matrigel coated transwell barrier (Fig. 
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11c), a less protrusive phenotype in 3D cell culture (Fig. 12), and decreased 
vascularization and wound closure in the avian embryo CAM assay (Fig. 13). 
Intriguingly, the migratory ability of these cells is not impaired. MDA-MB-231 BB-94 
treated cells do not exhibit changes in the active forms of the MT1-MMP protein, nor 
ERK1/2 phosphorylation, therefore supporting unchanged migratory ability, and the 
changes observed during invasion can be attributed to proteolysis alone.  
A number of observations have been made regarding MT1-MMP activity influencing the 
migration of cells in a manner not dependent on proteolytic activity. These include amino 
acid sequences in the catalytic domain that do not impact enzymatic activity (Woskowicz 
et al., 2013), and interactions of ECM substrates with the hemopexin domain of MT1-
MMP to initiate MAPK signalling (Zarrabi et al., 2011). In further support of these non-
catalysis dependent migration-promoting characteristics of MT1-MMP, migratory 
abilities of MDA-MB-231 cells were not impaired when treated with BB94. Treating 
these cells did not impact migration to close a wound in the scratch wound closure assay 
(Fig. 11a and b), nor did it impact migration though a porous barrier in the transwell 
migration assay (Fig. 11c). As migration alone does not require degradation of ECM 
constituents, and relies more on cytoskeletal rearrangements, the changes observed in 
MMP-2 and MMP-9 mRNA levels are assumed not to impact this cell motility event. 
Invasion on the other hand, was considerably impacted by inhibition of MMP catalytic 
activity, as all MT-MMPs present on the cell surface and all soluble MMPs secreted by 
MDA-MB-231 cells would have inhibited enzymatic activity. This is evident based on 
decreased transwell invasion (Fig. 11c) and a noticeably less protrusive phenotype in 3D 
culture (Fig. 12). As BB-94 treated MDA-MB-231 cells do not have changes in MT1-
MMP protein levels or ERK1/2 phosphorylation, which are involved in invadapodia and 
cytoskeletal stabilization respectively, I postulated that the decreased protrusiveness of 
cells is attributed to MMP catalytic inhibition. Phenotypically, cells with MMP catalytic 
site impairment were much more aggregated compared to the elongated phenotype of 
control MDA-MB-231 cells. BB-94 treated cells appear to have gone from an elongated 
mesenchymal morphology, seen in untreated MDA-MB-231, to a more amoeboid 
ellipsoid shape. This transition is often seen when MMPs or serine proteases are 
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inhibited. Cells adapt to altered catalytic abilities by using a protease-independent 
amoeboid method of movement involving weak interactions with surrounding matrix in 
order to passively move through existent spaces within the ECM (Fiedl and Wolf, 2003). 
BB-94 impaired invasion was apparent in CAM vascularization of artificial Matrigel 
tumours. These tumours showed decreased vascularization and inhibited wound closure 
following consistent application of BB-94 inhibitor (Fig. 13). In clinical application, BB-
94 has been shown to convert ascite tumours into avascular tumours in mice with cervical 
carcinoma xenografts (Davies et al., 1993, Lu et al., 2011). In these conditions, BB-94 
did not affect cell proliferation or migration, but did inhibit endothelial cell sprouting and 
morphogenesis, preventing the formation of complex networks and tubule-like structures. 
This suggests BB-94 may inhibit both early and late stages of angiogenesis. As the CAM 
tumour vascularization assay involves a whole functioning organism, it is uncertain to 
attest the reduction in tumour vascularization to inhibition of MMP catalytic ability of 
MDA-MB-231 cells within the tumour or to surrounding endothelial cells within the 
avian embryo CAM.  
Investigating the implications of pan-MMP inhibition in invasive MDA-MB-231 breast 
cancer cells has demonstrated a compensatory effect of increased MT1-MMP and MMP-9 
expression when MMP catalytic activity is inhibited. However, increased expression of 
MT1-MMP and MMP-9 is ineffective in rescuing invasive potential in 2D and 3D space, 
as well as in vivo tumour vascularization.  
4.3 MT1-MMP overexpression in MDA-MB-231 breast 
cancer cells altered pro- and active forms of MT1-MMP 
and inversely affects gelatinase expression  
Instead of chemically altering pro- and active MT1-MMP levels in MDA-MB-231 breast 
cancer cells, MT1-MMP overexpression cell lines were generated from these parental 
cells to further increase total MT1-MMP protein present within cells. Compared to 
parental MDA-MB-231cells, MDA-MB-231 C2 and C3 cell lines both have moderate 
amounts of pro- and predominately active MT1-MMP (Fig. 9a). Additionally in these 
cells MMP-2 and MMP-9 mRNA levels are altered, where both cell lines have decreased 
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MMP-2 and increased MMP-9 mRNA and protein levels (Fig. 9b and c). This was also 
seen with MCF-7 C2 and MDA-MB-231 cells treated with BB-94 (Fig. 4d and 5c), where 
overall MT1-MMP protein increase consisted of predominately active MT1-MMP (MCF-
7 C2 cells), with similar increased MMP-9 mRNA and decreased MMP-2 mRNA levels 
as a result (MCF-7 C2 and MDA-MB-231 cells). 
MDA-MB-231 C1 cells displayed both excessive pro- and active forms of MT1-MMP. 
Together with this MT1-MMP overexpression, MMP-2 mRNA levels are increased and 
MMP-9 mRNA levels are decreased. This cell line in particular demonstrates that there 
are optimal levels of active MT1-MMP needed to influence MMP-9 expression. Whereby 
MMP-9 expression could be decreased by the amount of pro-MT1-MMP present or 
through repression or activation of cell signalling pathways, such as MAPK and 
PI3K/AKT respectively. Most importantly, the genetic modification of MT1-MMP 
overexpression in MDA-MB-231 cell lines supports the continually observed inverse 
relationship of expression of the two gelatinases, and the contribution active MT1-MMP 
plays in cell signalling to influence MMP-9 expression.  
4.4 Inhibiting furin convertase activity alters MT1-MMP 
activation, inversely effects gelatinase expression, and 
alters cell migratory and invasive potential 
In this section, I will examine the role of inhibition of MT1-MMP activation on MMP 
expression as well migration and invasive potential of breast cancer cells. Treatment of 
MCF-7, MCF-7 C2, and MDA-MB-231 cells with furin convertase inhibitor, Furin 
Inhibitor I, decreased MMP-9 mRNA levels and increased MMP-2 mRNA levels (Fig. 6c 
and 7c). Only MCF-7 C2 cells showed decreased MT1-MMP mRNA and active MT1-
MMP protein levels, when treated with Furin Inhibitor I (Fig. 6a and b). As treatment of 
MDA-MB-231 cells with the furin inhibitor did not alter MT1-MMP protein forms, a 
stable MDA-MB-231 line (231-PDX) was created. 231-PDX cells overexpress α1-PDX, 
a small peptide that elicits the same effect as Furin Inhibitor I, to bind and block the 
active site of furin. These 231-PDX cells where furin activity is lower, exhibited 
increased MT1-MMP mRNA levels, and consequently, more of both pro-MT1-MMP and 
active MT1-MMP (Fig. 8). Additionally, 231-PDX cells have more phospho-ERK1/2 and 
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more MMP-9 mRNA in agreement with the proposed model of phospho-ERK1/2 directly 
influencing MMP-9 expression.  
4.4.1 Chemical inhibition of furin decreased levels of 
active MT1-MMP, phospho-ERK1/2, and MMP-9 
mRNA, but increased MMP-2 mRNA, and did not 
change cell migratory ability 
Active MT1-MMP present on the cell surface is dictated by intercellular activation within 
the Golgi and trans-Golgi network through a protein convertase called furin (Seidah et 
al., 2008). Inhibition of furin in MCF-7 C2 and MDA-MB-231 breast cancer cell lines 
resulted in decreased phospho-ERK1/2, decreased MMP-9 mRNA levels, and increased 
MMP-2 mRNA levels. The consistency between the two cell lines regarding decreased 
phospho-ERK1/2 signalling, and inverse expression of the gelatinase MMPs 
demonstrates a conserved mechanism for influencing MMP-2/-9 expression.  
MCF-7 C2 cells exhibited a dose dependent decrease in active MT1-MMP and phospho-
ERK1/2 levels following treatment with Furin Inhibitor I (Fig. 6a and b), while MDA-
MB-231 cells showed decreased MT1-MMP mRNA and ERK1/2 phosphorylation levels, 
but unaltered MT1-MMP protein forms (Fig. 7). Additionally, both cell lines when 
treated with Furin Inhibitor I, demonstrated the inverse mRNA level relationship seen 
with the two gelatinases, where MMP-9 mRNA levels were decreased and MMP-2 
mRNA levels were increased at 20 μM treatment. The results from furin inhibited MCF-7 
C2 cells, which showed decreased active MT1-MMP, phospho-ERK1/2 and MMP-9 
mRNA levels, further supports the hypothesis that active MT1-MMP is necessary for 
MAPK pathway activation, and phospho-ERK1/2 acts directly to influence MMP-9 
expression. Regulation of MMP-2 expression is not directly regulated by phospho-
ERK1/2, but attributed to crosstalk between MAPK and other pathways. Furthermore, the 
dose-dependent treatment of MCF-7 C2 cells with Furin Inhibitor I, highlights the 
importance of a proper stoichiometric relationship between the levels of active MT1-
MMP and MMP-2. Cells treated with 5 μM and 10 μM of the inhibitor have relatively 
more active MT1-MMP and less MMP-2 mRNA, while cells treated with 20 μM of the 
inhibitor have less active MT1-MMP and more MMP-2 mRNA. It is interesting that in a 
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situation where there is less active MT1-MMP, which is needed to active pro-MMP-2, 
that there is upregulation of the expression of MMP-2. In this case, I predicted that 
decreased activation of pro-MMP-2 on the cell surface is resulting in a feedback 
mechanism to increase MMP-2 transcription. 
In terms of cell motility, the migratory ability of MDA-MB-231 cells treated with Furin 
Inhibitor I observed via a scratch wound closure assay, was not impaired (Fig. 11a and b). 
MT1-MMP is known to be found in the leading edge of a migrating cells (Friedl and 
Wolf, 2003), and as MT1-MMP protein levels were unaffected in Furin inhibitor I treated 
MDA-MB-231 cells, it is unsurprising that treated cells retained migratory efficiency. 
Although phospho-ERK1/2 levels are decreased (Fig. 7a and b) in treated MDA-MB-231 
cells, migration is not (Fig. 11a and b), and it poses the question of the proportional 
amount of phospho-ERK1/2 needed to stabilize actin-associated structures and promote 
cell motility. 
4.4.2 Overexpression of α1-PDX increased active MT1-
MMP, phospho-ERK1/2, MMP-9 mRNA levels, but 
decreased MMP-2 mRNA in MDA-MB-231 cells 
As chemical inhibition was ineffective in changing MT1-MMP activation in MDA-MB-
231 breast cancer cells, the stable cell line 231-PDX was created overexpressing α1-PDX, 
a small peptide that inhibits the convertase activity of furin (Thomas, 2002). 231-PDX 
cells have more total MT1-MMP protein, both pro and active forms, compared to MDA-
MB-231 cells (Fig. 8b and c). Additionally, these cells have increased phospho-ERK1/2 
and elevated MT1-MMP mRNA levels (Fig. 8c and d). 231-PDX cells also exhibited an 
inverse expressional relationship between MMP-2 and MMP-9, decrease and increase 
respectively (Fig. 8d).  
Although it was expected that overexpression of α1-PDX and resultant furin inhibition 
would cause less active MT1-MMP, the presence of more pro- and active MT1-MMP 
was a surprising result. However, increased levels of active MT1-MMP are still 
consistent with my overall hypothesis, as 231-PDX cells also had elevated ERK1/2 
phosphorylation and increased MMP-9 mRNA. However, altering MT1-MMP activation 
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in MDA-MB-231 cells did not induce changes in levels of transcription factors AP-1 and 
NF-κB (Fig. 10c and d), therefore other transcription factors which are regulated by 
phospho-ERK1/2 and are MMP-9 specific, such as RCE, TIE, or KRE, or MT1-MMP 
specific, Sp-1, should be assessed in 231-PDX cells (Overall and López-Otín 2002). 
Increased active MT1-MMP levels following expression of α1-PDX has been noted in 
other cancerous cell lines as well, including squamous cell carcinoma, epidermoid 
carcinoma cells, and pharyngeal carcinoma cells (Bassi et al., 2001). Additionally, CHO 
cells co-transfected to secrete a soluble form of MT1-MMP and α1-PDX, displayed an 
increase in total MT1-MMP protein with predominately active MT1-MMP (Coppola et 
al., 2008). MT1-MMP has been found to be activated through furin-independent 
mechanisms primarily by other active MMPs (Rozanov et al., 2001; Sato et al., 1999). 
For example there is evidence that MT1-MMP may undergo a two-step activation 
process, including autocatalysis (Strongin, 2010). If furin-dependent mechanisms of 
activation are being inhibited by α1-PDX peptides, it is possible that feedback occurs to 
transcriptionally upregulate MT1-MMP expression, and additional pro-MT1-MMP 
proteins are being translated and activated by a furin-independent manner to result in 
increased active MT1-MMP present within 231-PDX cells.  
4.4.3 Overexpression of α1-PDX in MDA-MB-231 cells 
exhibit decreased migration and invasive potential  
231-PDX cells are the only experimental cell in this study that exhibited high increased 
levels of active MT1-MMP protein and MMP-9 mRNA, accompanied by moderately 
increased ERK1/2 phosphorylation, all features that could increase cell migration and 
invasion. Nonetheless, 231-PDX cells exhibited decreased transwell migration, decreased 
transwell invasion (Fig. 11c), decreased protrusions in 3D cell culture (Fig. 12b), and 
decreased vascularization and wound closure in an avian embryo CAM wound assay 
(Fig. 13).  
In 3D cell culture, 231-PDX cells have a very round morphology, with fewer protrusions 
than MDA-MB-231 cells, and lack the meschenymal-like elongated cell phenotype. 231-
PDX cells are morphologically most like MDA-MB-231 C2 cells —circular and round, 
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with decreased protrusions (Cepeda et al., 2016). Furthermore, MDA-MB-231 C2 cells 
have increased total MT1-MMP mRNA compared to MDA-MB-231 parental cells and 
high active MT1-MMP protein, increased MMP-9 mRNA but decreased MMP-2 mRNA 
(Fig. 9), all similar features of 231-PDX cells. Through analysis of both MCF-7 and 
MDA-MB-231 MT1-MMP overexpression cell lines, Cepeda et al (2016) found that as 
levels of MT1-MMP overexpression increased, the migratory and invasive potential of 
breast cancer cells decreased, and 231-PDX cells fit into this categorization as 
exemplified by transwell migration and invasion assay. Furin also cleaves a wide variety 
of substrates in addition to MT1-MMP, such as TGF-β, stromolysin-3, growth factors, 
and adhesion molecules, which are also important for proper cell motility (Strongin, 
2010). Activation of other furin substrates could be altered by the presence of α1-PDX 
peptides and additionally be contributing factors in decreased cell migration, invasion, 
and altered cell morphology in 231-PDX cells.  
Analysis of vascularization and wound closure of 231-PDX comprised Matrigel tumors 
in an avian CAM assay revealed intermediate incidences of vascularization and variable 
wound closure (Fig. 13c). This assay is very general, and it is difficult to assess if lack of 
vascularization and wound closure is attributed to decreased migratory and invasive 
potential of 231-PDX cells, altered MMP expression, changes in TGF-β, growth factors, 
or adhesion molecules, or due to changes in secreted VEGF family members. MDA-MB-
231 naturally express high levels of VEGF family members needed to promote 
development of new vasculature (Di Benedetto et al., 2015) whereby cleavages of VEGF 
are executed by MMP-9 (Bergers et al., 2000; Yu and Stamenkovic 2000). It is possible 
that in modulating MT1-MMP protein forms, resultant ERK phosphorylation levels, and 
MMP-9 expression, that other aspects needed for cell movement and angiogenesis were 
altered as well in order to produce this very intermediate characterization of 
vascularization and wound closure. 
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Chapter 5 
5 Conclusion 
 
MT1-MMP proteolytic and non-proteolytic functions are strongly implicated in the 
promotion and progression of cancer by promoting cell migration and invasion. As 
shown here, by disrupting ERK1/2 phosphorylation, MMP catalytic activity, or MT1-
MMP activation, the migratory and invasive potential of MDA-MB-231 breast cancer 
cells is impaired. I initially hypothesized that the levels of phosphorylated ERK1/2 would 
be proportional to the levels of active MT1-MMP, and be correlated with increased 
MMP-2 and MMP-9 mRNA and increased invasive potential of breast cancer cells.  
 
Inhibition of ERK1/2 phosphorylation caused decreased MT1-MMP mRNA and 
subsequently decreased active MT1-MMP protein levels. This resulted in decreased 
ERK1/2 phosphorylation and subsequent decreased NF-κB transcriptional activity. 
However the mRNA levels of the two gelatinases were not affected proportionally to 
ERK1/2 phosphorylation — an inverse relationship between MMP-2 (increased mRNA) 
and MMP-9 (decreased mRNA) was observed indicating MMP-9 expression was more 
directly controlled by phospho-ERK1/2. Cells with reduced active MT1-MMP levels 
exhibited decreased migratory and invasive potential. Inhibition of MMP catalytic 
activity by BB-94 caused an increase in phospho-ERK1/2 and successive increased MT1-
MMP mRNA and protein levels. Furthermore, following BB-94 treatment phospho-
ERK1/2 was increased and gelatinase expression was inversely associated —increased 
MMP-9 mRNA and decreased MMP-2 mRNA, and invasive potential was reduced. The 
effect inhibition of MT1-MMP activation, by the inhibition of furin, was dependent on 
mode of inhibition. Chemical alteration of furin convertase activity caused decrease 
active MT1-MMP, decreased phospho-ERK1/2, decreased MMP-9 mRNA levels, and 
decreased MMP-2 mRNA levels. However, counter to my original hypothesis, invasive 
potential was not increased despite having increased active MT1-MMP protein, phospho-
ERK1/2 and MMP-9 mRNA. Therefore cells that have levels of phospho-ERK1/2, active 
MT1-MMP, or MMP-9 mRNA above or below their endogenous levels, invasive 
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potential is reduced. Additionally, despite the gelatinase MMPs sharing substrate 
similarity, this study proposes that altering MMP-2 or MMP-9 expression and proposed 
functions do not compensate for one another in vitro. As consequential to chemical or 
genetic alteration of cell specific components, MMP-2 and MMP-9 expression was 
always effected in an inverse manner (Fig. 14).  
 
Through targeting of different proteolytic and non-proteolytic functions of MT1-MMP 
this study proposes that active MT1-MMP is needed for induction of MAPK signalling 
causing increased phospho-ERK1/2. Phospho-ERK1/2 then influences MT1-MMP and 
MMP-9 specific transcription factor NF-κB to ultimately regulate their respective 
expression. MMP-2 expression is indirectly regulated through proposed feedback 
mechanisms and signalling pathway cross talk. This study demonstrates the difficulty of 
designing direct protein targeting cancer therapeutics, as MMP and cell signalling 
functions are complexly intertwined.   
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Figure 14. Proposed cell models individually outlining cellular outcomes of 
inhibiting ERK1/2 phosphorylation, MMP catalytic activity, or altering of MT1-
MMP activation via changes in MMP transcription and protein levels, ERK1/2 
phosphorylation, and cell motility. 
(a) Treatment of breast cancer cells with MEK1/2 inhibitor (U0126) resulted in decreased 
ERK1/2 phosphorylation, decrease in the activity of MT1-MMP and MMP-9 specific 
transcription factor NF-κB, but no change in AP-1 transcription. Levels of MMP-2 
mRNA were increased, while mRNA levels of MMP-9 and MT1-MMP were decreased.  
Consequently, there was less overall MT1-MMP (less pro- and active) protein. Moreover, 
migration and invasive potential was decreased in cells treated with U0126. (b) 
Treatment of breast cancer cells with the pan-MMP inhibitor (BB-94) resulted in 
decreased MMP catalytic activity. Subsequently, BB-94 treated cells displayed decreased 
ERK1/2 phosphorylation, but no change in the activity of transcription factors AP-1 and 
NF-κB. However, MMP mRNA levels were altered. MMP-2 mRNA was decreased, 
while MMP-9 and MT1-MMP mRNA was increased As a result, cells treated with BB-94 
had more MT1-MMP protein overall, with an increase in both pro- and active forms. 
Furthermore, inhibition of MMP catalytic activity did not influence migratory potential, 
but decreased invasive potential. In this BB-94 treatment, it is possible that an alternative 
pathway influences MMP expression, as more active MT1-MMP did not result in an 
increase in phospho-ERK1/2, nor was the activity of transcription factors changed. (c) 
Altering MT1-MMP activation by chemical inhibition (Furin inhibitor I) reduced active 
MT1-MMP protein levels. Decreased levels of active MT1-MMP resulted in decreased 
phospho-ERK1/2 as well as decreased MT1-MMP and MMP-9 mRNA levels, but 
increased MMP-2 RNA levels. Altering MT1-MMP activation did not change the 
migratory potential of cells. As Furin Inhibitor I elicited a weaker effect on MDA-MB-
231 cells than U0126 or BB-94, stable MDA-MB-231 breast cancer cells were generated 
expressing Alpha1-Antitrypsin Portland, as an alternative approach to block MT1-MMP 
activation. (d) MDA-MB-231 cells stably overexpressing α1-PDX, 231-PDX, displayed 
more pro- and more active MT1-MMP compared to MDA-MB-231 parental cells. This 
resulted in increased phospho-ERK1/2 but decreased activity of NF-κB and no change in 
activity of AP-1. However, MMP-9 and MT1-MMP mRNA was increased, and MMP-2 
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mRNA was decreased. Migratory and invasive potential was decreased in 231-PDX cells. 
Ultimately, the results from each respective treatment propose a pathway in which active 
MT1-MMP is needed to initiate the MAPK pathway resulting in subsequent ERK1/2 
phosphorylation, activation of NF-κB, expression of MMP-9. 
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